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 Histamine and serotonin are important neurochemicals that maintain crucial brain 
functions. Both are thought to be altered in affective and neurodegenerative disorders such 
as depression and Parkinson’s disease. Histamine and serotonin are thought to modulate 
one another but the exact relationship remains unknown and this gap in knowledge makes 
diagnosing and treating disorders involving the transmitters difficult. The Hashemi lab 
studies serotonin neurochemistry to understand serotonin’s role in psychiatric disorders. 
However, histamine has remained an understudied neurotransmitter due to a lack of 
analytical tools. In 2015 and 2016, the Hashemi lab pioneered a novel detection method 
utilizing fast-scan cyclic voltammetry (FSCV) for the real-time detection of histamine and 
serotonin in vivo. Using this method, we are able to visualize the real-time modulation of 
serotonin by histamine through H3 receptors. The work herein furthers our understanding 
of the histaminergic system in the brain and its modulation of serotonin. First, we provided 
a review of analytical methods for monitoring neurotransmitters in the brain (Chapter 2). 
Then we pharmacologically challenged various aspects of the histaminergic systems of 
male and female mice and show the highly conserved nature of the brain (Chapter 3). This 
study also revealed that female mice may have a more tightly regulated brain histamine 
system controlled by cycling hormones. Next, we investigated the synaptic transport 
mechanisms of histamine and utilized a genetically modified mouse model to rule out the 
contribution of the serotonin transporter towards histamine clearance (Chapter 4). After we 
characterized the histamine system and its clearance mechanism, we applied histamine 
 vii 
FSCV to a chronic stress mouse model of depression (Chapter 5). We found brain 
histamine was elevated during chronic stress and inflammation; this has large implications 
given the comorbidity of psychiatric disorders and chronic inflammation. Finally, we 
investigated the effect of ketamine, the newly approved antidepressant and anti-
inflammatory compound, on histamine transmission and subsequent serotonin modulation 
(Chapter 6). Collectively, this dissertation furthers our understanding of histamine and 
serotonin modulation and the mechanisms governing their transmission. Novel discoveries 
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1.1 Brain Signaling via Chemical Transmission 
A major paradigm shift occurred in the late 1950s and 1960s when the 
understanding of brain communication shifted from electrical signaling to chemical 
signaling.1 The chemical messengers responsible for relaying signals from the brain to the 
periphery would come to be known as neurotransmitters. Histamine is a bioaminergic 
neurotransmitter responsible for myriad processes in both the peripheral and central 
nervous systems and is capable of modulating other chemicals in the body. One key 
neurotransmitter that histamine modulates is serotonin (5-hydroxytryptamine; 5-HT). The 
dysregulation of both histamine and serotonin have been implicated in psychiatric and 
neurodegenerative diseases like depression and Parkinson’s disease.2-5 Understanding the 
underlying chemical miscommunication is a critical component of diagnosing and 
accurately treating diseases of the brain and the absence of robust tools to do so hinders 
treatment advances. The Hashemi lab specializes in developing and using electrochemical 
tools to understand the unique neurochemistry of histamine and serotonin in vivo in 
rodents. Relative to the serotonergic system, the histaminergic system remains 
understudied in the context of psychiatric and neurodegenerative diseases, especially when 
studied simultaneously. The Hashemi lab optimized an electrochemical technique that 
allowed for simultaneous, real-time, in vivo detection of histamine and serotonin in rodent 
brains. This current work furthers our understanding of the CNS histaminergic system and 
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the implications in inflammatory states. The focus of this dissertation will be analyzing and 
understanding the modulatory effects of histamine on serotonin in healthy and 
inflammatory states using electroanalytical chemistry. This will be accomplished in several 
chapters: 1) Reviewing analysis methods for neurotransmitters; 2) Investigating 
differences between the male and female histaminergic system in the context of 
pharmaceutical challenges in mice; 3) Studying the transport mechanisms of histamine in 
the CNS; 4) Determining how histamine is altered in models of inflammation and 
neurodegeneration; and 5) Investigating how an atypical antidepressant affects 
histaminergic signaling. 
1.1.1 The Histaminergic System 
Histamine is a key bioamine neurotransmitter that has roles in circadian rhythm, 
arousal, appetite, and inflammation. 6-9 The enzyme L-histidine decarboxylase (HDC) is 
responsible for transforming histamine’s precursor molecule, the amino acid L-histidine, 
into histamine in the tuberomammillary nucleus (TMN) located in the hypothalamus.6-7 
Similar to other monoamine neurotransmitters (i.e. serotonin, dopamine, or 
norepinephrine), histamine is stored neuronally until its release, at which point it is 
packaged into vesicles via the vesicular monoamine transporter protein (VMAT).10-13 
Whereas serotonin, dopamine, and norepinephrine each have their own active, high-affinity 
transport mechanisms (serotonin transporter, SERT; dopamine transporter, DAT; 
norepinephrine transporter, NET), an analogous transport protein for histamine has not yet 
been identified.14-16 Brain histamine is thought to be exclusively degraded to tele-
methylhistamine by the intracellular histamine N-methyltransferase enzyme.17 It can then 
be further degraded into tele-methylimidazoleacetic acid via monoamine oxidase B and 
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aldehyde dehydrogenase.18-19 It is worth noting that this metabolic route is only available 
for central histamine; peripheral histamine undergoes its own specific degradation through 
diamine oxidase.14  
From the cell bodies in the TMN, histamine neurons project widely throughout the 
brain and spinal cord with the densest innervations ascending to the hypothalamus.20-21 
There have been four receptors identified associated with the histaminergic system: H1R, 
H2R, H3R, and H4R, all of which belong to the rhodopsin-like family of G protein-coupled 
receptors.6 Receptors H1, H2, and H3 are expressed in large amounts throughout the brain 
and while there is some recent evidence for H4R mRNA expression in neuronal cells and 
microglia, the science remains unsettled.6, 22-25 However, it is important that H4R are widely 
expressed in mast cells which can cross the blood brain barrier (BBB).26-27 
The H1 receptor is post-synaptically located and activation leads to neuronal 
excitation. Arousal and feeding behavior have been linked to H1R activation using 
knockout models to visualize behavioral deficits associated with H1 impairment.28-32 
Common over-the-counter antihistamines (diphenhydramine and loratadine; brand names 
Benadryl® and Claritin®, respectively) target this receptor to block H1 activation and 
signal propagation. H2R is expressed throughout the brain and localized post-synaptically 
similar to H1R, but is more consistently localized with HA projections.33-34 Particularly 
high expression is found in the amygdala and hippocampus where H2R deficient mice 
display cognitive impairments.35 Additionally, H2R targeted therapies are commonly 
prescribed for the alleviation of gastric disorders as H2R has been shown to mediate gastric 
secretion.36-37 The H3 receptor, identified in 198338 and cloned in 199939, is unique in its 
location and ability. It is located presynaptically on HA neurons and functions as an 
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inhibitory autoreceptor controlling the release and synthesis of histamine.40-41 H3R is also 
able to exert modulatory control over other neurotransmitter systems through locations on 
presynaptic terminals of serotonin42, dopamine43, norepinephrine44, glutamate45, GABA46, 
and acetylcholine.47 As such, the H3 receptor rapidly became a target for various 
therapeutic strategies.48-50 Animals lacking H3R show enhanced susceptibility to CNS 
inflammatory disease51 and behavior abnormalities.52 H4R are the most recently identified 
receptor subtype and subsequently the least understood as briefly discussed in the previous 
paragraph.53 The majority of H4R expression is confirmed in the periphernal nervous 
system in mast cells, basophils, and hematopoetic cells playing a critical role in the 
recruitment and activation of inflammatory cells.54-55 With similar function to H3R, H4R 
has also been highlighted for its therapeutic potential.56 
1.1.2 Histamine’s Role in Neurodegenerative and Psychiatric Diseases 
 Dysfunctions of the histaminergic system have been linked to physiological and 
behavioral abnormalities. In post-mortem analyses of patients diagnosed with Huntington’s 
disease, a significantly lower H3 receptor density was observed in areas of the dorsal 
striatum suggesting indirect impaired control of motor function neurons.57 Significant 
decreases in tuberomammillary neurons and H1 receptor binding are observed in 
Alzheimer’s disease patients.58-60 H1R knockout mice show pronounced impairment of 
spatial learning and memory and reduced neurogenesis.61 Decreased histamine throughout 
the CNS paired with blunted neurogenesis may partially explain the cognitive decline seen 
in AD patients. Parkinson’s disease (PD) patients have significantly higher histamine levels 
in the brain compared to age matched controls and show alterations in histamine receptor 
expression density.62-63 Similar results have been found in a rodent model of PD.64-65 
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Growing evidence highlights histamine’s role in psychiatric disorders like depression and 
anxiety. Histamine receptor binding was significantly less in patients with major depressive 
disorder compared to age-matched controls via positron emission tomography.66 Recently, 
an HDC knockout mouse revealed that chronic histamine depletion induced depression-
like phenotypes and impaired memory analyzed by the tail suspension, elevated zero maze, 
and Y-maze tests.67 
1.1.3 Histamine’s Role in Inflammation 
 Histamine is most well-known for its role in the immune system and inflammatory 
state. It is a critical signaling molecule that recruits pro-inflammatory proteins and markers 
to the site of a foreign body response.68 The foreign body response can range from 
something as common as the immune reaction to a splinter to oxidative stress in 
Parkinson’s disease. These examples highlight two distinct locations, the splinter in the 
peripheral nervous system – systemic inflammation – and oxidative stress – 
neuroinflammation. Systemic inflammation is marked by upregulation of microglia, 
recruitment of proinflammatory cytokines and a local increase in histamine levels.69 While 
neuroinflammation produces similar chemical markers, the effect on local levels of 
histamine remains unclear for several reasons. First, the brain is a unique, dynamic medium 
that is analytically challenging to probe. Secondly, histamine is present in the brain at 
extremely low concentrations (nM-µM), therefore, techniques must possess the selectivity 
and sensitivity to capture these low concentrations. Third, histamine, itself, presents a 
distinct fundamental challenge to overcome due to ‘the observer effect’ – meaning, to 
measure histamine a probe must be inserted into the area of interest (eg. brain). This action 
inevitably causes a disruption of tissue and cellular communication and registers a foreign 
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body response. The inflammation resulting from probe insertion causes an inherent 
perturbation in histamine levels in the surrounding tissue that can result in techniques 
reporting varying concentrations of histamine. 
1.1.4 Sex Mediated Differences in the Histaminergic System 
 In 2015 the National Institutes of Health (NIH) ruled that all NIH funded research 
involving pre-clinical animal models must consider sex as a biological variable.70 
Previously, the majority of pre-clinical research was conducted using only the male sex to 
avoid complications from the female estrous cycle.71 This has led to several instances of 
untranslatable research between animal models and humans.72 Estrogen is shown to be a 
major regulator of eating behavior, lordosis, and anxiety through estrogen receptor alpha 
and beta (ER; ER) in the ventromedial nucleus (VMN) of the hypothalamus.73-75 In the 
VMN, H1R and ERα mRNA are co-expressed in histaminergic neurons.73, 76 ER is not as 
strongly expressed in the VMN as ER but is expressed in the TMN where histaminergic 
projections originate.77 The localization of estrogen receptors on histamine projections 
highlights the potential role estrogen plays in regulating immune response. Indeed, 
estrogen and progesterone have been shown to mitigate the acute inflammatory response 
to lipopolysaccharide exposure.78-81 Additionally, inflammatory diseases and the 
susceptibility to the occurrence of diseases are more likely in post-menopausal women than 
pre-menopausal women and age matched males.82-83 
1.1.5 Classical Versus Atypical Antidepressants 
 Since the discovery that the main therapeutic effects of early antidepressants were 
due to targeting the monoaminergic systems of dopamine, norepinephrine and serotonin, 
the field has remained focused on optimizing strategies to increase levels of these in the 
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brain.84 Broadly, these monoamine targeting antidepressants are grouped into ‘classical’ 
antidepressants adhering to the monoamine hypothesis, but research drive for these classic 
antidepressants has steadily weaned.85-86 At the turn of the century a revised monoamine 
hypothesis was being constructed that brought the glutamatergic system to the forefront.87 
The modulatory roles that glutamate and GABA play on the monoamines is being explored 
as a new potential therapeutic route for antidepressants.88 Ketamine, an NMDA receptor 
antagonist, became a molecule of interest for its rapid acting antidepressant activity when 
administered in subanesthetic doses.89 The exact mechanism(s) of the new rapid acting 
antidepressants are still unknown and its clear they involve several complicated 
biochemical pathways.90-95 As an antidepressant and anti-inflammatory, we are interested 
in understanding ketamine’s effects on central histamine. 
1.1.6 Motivation for this Dissertation 
 Given the information above, exploring the fundamental neurochemical actions of 
histamine within the brain presented a unique and challenging opportunity. The Hashemi 
lab is deeply focused on the chemical underpinnings of psychiatric diseases, specifically 
depression, and the nexus of histamine and serotonin holds the potential of being a rich 
body of information. Therefore, my work herein, focuses on furthering the community’s 
understanding of the relationship between the histaminergic and serotonergic systems and 
their co-modulation. As mentioned above, measuring chemicals in the brain is a great 
challenge; requiring technical ability in addition to niche tools that fulfill strict criteria. An 
ideal method must have the selectivity to discern between structurally and chemically 
similar neurotransmitters and metabolites, high sensitivity to monitor the low extra-
synaptic analyte concentrations, a high temporal resolution to capture the sub-second 
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neurotransmission process, and the micro- dimensions to target specific brain regions of 
interest while causing minimal disruption to the surrounding tissue in vivo. Electrochemical 
methods utilizing carbon electrodes are promising for such a challenging task. 
1.2 Analysis of Neurotransmitters in the Brain 
 The brain is a dynamic medium in a delicate homeostasis. As stated above, 
monitoring the chemicals present in the brain necessitates selectivity, sensitivity, temporal, 
and size requirements. Detection and quantification methods can be delineated into two 
main categories: microdialysis (followed by separation and detection) and direct 
electrochemical analysis, each with their respective benefits and drawbacks. For the 
purposes of this dissertation, only electrochemical methods will be discussed.  
Electroanalytical methods are favorable for neurochemical analyses due to the 
ability to quantify species through direct oxidation and reduction. Carbon electrodes have 
proven to be the most commonly used implantable electrochemical probe due to its relative 
inertness, abundance, cost efficiency, wide potential window, and rich surface chemistry.96-
97 Specifically, carbon fiber microelectrodes (CFMs) are extensively used in the field of 
monitoring neurotransmitters as they are biocompatible, stable, minimally invasive, and 
have favorable electrochemical properties.98 The CFM surface is an electrochemically rich 
environment covered in striations and electrostatically charged oxygen functionalities (-
OH, C=O, COOH/COO-) that result in an adsorptive substrate.99 Thus, the CFM is a go-to 
tool for direct electrochemical analysis of neurotransmitters in vivo. 
1.2.1 Electrochemical Methods Utilizing CFMs 
CFMs are covered in striations that create a rich surface for electrochemical 
activity. The obvious drawback of electroanalytical methods is the key criterion that an 
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analyte of interest must be readily oxidizable in the given potential window of the electrode 
material. Several key bioamines in the brain, dopamine, serotonin, and histamine, are in 
fact oxidizable within the potential window for carbon. In the 1960s, Ralph Adams 
conducted his seminal work using crudely fabricated carbon paste disc electrodes 
constructed from graphite powder mixed with mineral oil packed into Teflon tubing.100 
These electrodes were used to carry out foundational electrochemical analyses of 
catecholamines.101-102 
 
Figure 1.1: A scanning electron micrograph of 
a carbon fiber microelectrode. 
 
 Amperometry involves holding an electrode at a constant potential while measuring 
the current from analytes undergoing oxidization at the surface. This method excels at 
temporal resolution (< 1 ms) as oxidation is only limited by diffusion to the electrode 
surface since potential is constant.103 Unfortunately, holding at a specific voltage oxidizes 
all analytes with oxidation potentials under that voltage and, thus, amperometry suffers 
from a lack of chemical specificity which is critical when probing the brain. Amperometry 
at carbon disks, fibers, and microelectrode arrays has been used extensively to study the 
vesicular events of single cells ex vivo.104-105 These studies aim to further the understanding 
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of neurotransmission by studying vesicle fusion pore size, duration, and the amount of 
contents release during an event.106-107 
 Chronoamperometry was developed to increase the selectivity afforded by 
amperometry. Chronoamperometry uses a square wave step function between an upper and 
lower potential limit. The ratio of peak oxidative current to peak reductive current is able 
to yield information about the analyte identity. There is a large capacitive (non-faradiac) 
current associated with potential pulse that decays rapidly, while the faradiac current 
decays more slowly over time. Analyte information is obtained through the relationship of 
redox current over time. This technique has been used to study psychiatric models108, 
transport kinetics109-110, and drugs of abuse.111 Despite its improvements over 
amperometry, chronoamperometry is still limited in scope and selectivity. 
1.2.2 Fast-Scan Cyclic Voltammetry 
 Pioneered by R. Mark Wightman and Julian Millar in the mid 1980s, fast-scan 
cyclic voltammetry (FSCV) (originally termed fast cyclic voltammetry) emerged as a new, 
selective method to monitor the release and reuptake of dopamine in vivo by direct 
electrochemical means at CFMs.112-113 FSCV has become a primary technique used by 
electrochemists, neuroscientists, and pharmacologists to monitor neurochemicals in the 
brain. As in traditional cyclic voltammetry, FSCV uses the combination of 2 or more linear 
voltammetric sweeps (eg. A → B → A) while measuring the current from redox processes 
occurring at the working electrode. This set of instructions that dictates how the potential 
of the working electrode is changed with respect to time is called a waveform and is the 
primary source of selectivity. FSCV employs significantly faster scan rates (100s – 1000s 
V s-1) than traditional cyclic voltammetry (typically <100 mV s-1) that result in a large 
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capacitive current. This necessitates background subtraction to remove it. Therefore, FSCV 
is only capable of recording changes in a system and reports data as a change from baseline. 
In vivo, this change is typically induced through electrical, pharmacological, or optical 
stimulation of neurotransmitter release.114-116 
An FSCV data set is collected on a sub-second timescale. The fast scan rate results 
in the potential window being traversed in <10 ms, and the application frequency of 10 Hz 
allows for analytes to preconcentrate on the electrode surface at the holding potential for 
>90 ms, thereby increasing sensitivity. Scanning from the resting potential to the positive 
limit is called the anodic scan, where oxidation of the analyte will occur. Once the limit is 
reached, the scan direction is switched, and the cathodic scan begins, during which 
reduction occurs, until the negative limit is reached. The rapid switch in scan direction 
results in the aforementioned large capacitive current due a phenomenon known as the 
electrical double layer.117-118 Data obtained through a complete scan of the waveform is 
plotted as current vs voltage to create an analyte-specific cyclic voltammogram (CV) used 
for both qualitative and quantitative analysis. FSCV software collects the CVs and stacks 
them in chronological order to construct a 3D plot of current vs voltage vs time. For ease 
of interpretation, 3D plots are visualized from a bird’s-eye view, termed color plots, where 
current is assigned a false color as seen in Figure 1.2A. Importantly, a vertical line through 
the color plot provides the CV and a horizontal line will detail how current is changing 
over time. 
It was only recently that FSCV was expanded for the analysis of neurochemicals 
other than dopamine in vivo. Serotonin detection via FSCV is very difficult due to low 
extracellular concentrations and the metabolite, 5-hydroxyindoleacetic acid, is present at 
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much higher concentrations and fouls the electrode surface.119 To overcome the surface 
fouling, a thin layer of Nafion, a cation exchange polymer, is electrodeposited onto the 
CFM.119 
 
Figure 1.2: Serotonin FSCV(A) Representative serotonin color plot with a 
characteristic serotonin CV inset. The green event corresponds to serotonin 
oxidation occurring around 0.7 V. Abstracting the vertical dashed line will 
reconstitute the inset CV. (B) Concentration vs time profile for the stimulated 
release and reuptake of serotonin. B is obtained by following the horizontal 
dashed line in A. The light blue bar at the bottom represents the 2 s electrical 
stimulation. 
 
We measure serotonin dynamics in the CA2 region of the hippocampus by 
stimulating a dense tract of nerves that innervate numerous brain regions called the medial 
forebrain bundle (MFB). Figure 1.2 shows a typical data set obtained for the stimulated 
release of serotonin in the CA2. Figure 1.2A is a representative serotonin color plot with 
an inset CV in the right corner. Interpretation of the color plot is described in detail 
elsewhere.120 Briefly, time is on the x-axis, voltage is on the y-axis, and current is 
represented in false color. The green event corresponds to the oxidation of serotonin around 
0.7 V. Figure 1.2B shows a typical profile of stimulated serotonin release and reuptake 
over time as [5-HT] vs time. Background is collected for 5 s followed by a 2 s stimulation, 
denoted by the light blue bar, resulting in the release of serotonin which reaches a 
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maximum amplitude around 7.5 s where the rate of reuptake now overtakes the rate of 
release following the end of the stimulation and the curve decays to baseline as serotonin 
is reuptaken into the cells. 
In 2015, the Hashemi lab expanded the scope of FSCV once again by pioneering a 
novel, selective waveform for the detection of histamine in vivo that scans from -0.5 V to 
-0.7 V to 1.1 V to -0.5 V at 600 V s-1.121 This method is not only able to detect histamine 
but also serotonin simultaneously due to the potential window encompassing both 
neurotransmitters’ oxidation potentials.122 Using this technique, we showed that the 
stimulated release of histamine results in the rapid inhibition of serotonin release in the 
posterior hypothalamus of mice.122 Shown in Figure 1.3A is a representative color plot of 
the stimulated histamine release and subsequent serotonin inhibition. The green event 
corresponds to the release and reuptake of histamine and the blue/black event corresponds 
to the inhibition of serotonin. What is important to reiterate here is that FSCV is 
background subtracted and therefore only captures changes. The serotonin event is shown 
in blue, or negative current, which is only denoting that serotonin is decreasing with respect 
to its pre-stimulation levels. It is still occurring around 0.7 V, which is serotonin’s oxidation 
potential for FSCV. The stimulated release of histamine is shown in green because it is 
increasing with respect to its ambient concentration. Histamine FSCV uses a stimulation 
of the MFB to elicit the release of neurotransmitters, albeit a different placement along the 
tract to minimize serotonin release. Figure 1.3B shows the corresponding concentration vs 
time plots for both histamine and serotonin together to better visualize the release-
inhibition relationship. Following stimulation (light blue bar) [histamine] increases (blue; 
top trace) and returns to baseline while the inhibition of [serotonin] (red; bottom trace) can 
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be seen as it reaches peak inhibition slightly after histamine’s peak release and returns to 
around 20 nM. Figure 1.3C is a representative CV collected for histamine FSCV. It is 
visually very different than a serotonin CV and difficult to interpret. The broad peak around 
0.2-0.3 V represents HA oxidation and the inverted peak around 0.7-0.8 V represents the 
serotonin oxidation (the oxidation peak is inverted due to serotonin levels decreasing with 
respect to ambient levels). 
 
Figure 1.3: Histamine fast-scan cyclic voltammetry in the mouse 
posterior hypothalamus. (A) Representative histamine FSCV color plot. 
The green event is stimulated histamine release (labeled ‘histamine’) and 
the blue even is the subsequent inhibited serotonin (labeled ‘serotonin’). 
(B) Release and inhibition vs time profiles of histamine (blue) and 
serotonin (red), respectively. Stimulation is shown as the light blue bar. 
(C) Characteristic histamine CV. Blue star shows the typical histamine 
peak around 0.3 V and red star shows the inverted serotonin oxidation 
peak around 0.7-0.8V. (D) Histamine FSCV waveform. 
 
The development of this novel waveform that enables the monitoring of two 
neurotransmitter systems simultaneously provides a tool to obtain critical information 
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about the modulatory relationship between histamine and serotonin and widens the scope 
of questions we are able to ask about the brain. 
1.3 Scope of the Dissertation 
 In this dissertation, I first provide a review of analysis methods for neurochemicals 
in the brain (Chapter 2). I then use histamine FSCV to characterize the male and female 
histaminergic system and their respective response to pharmaceutical challenge via 
voltammetry (Chapter 3). I then further investigated the reuptake mechanisms of histamine 
in male and female mice through use of a genetic mouse model (Chapter 4). After gaining 
an understanding of the functionality of the histaminergic system, I apply histamine FSCV 
to a model of chronic inflammation: behaviorally depressed mice (Chapter 5). Finally, I 
used histamine FSCV to understand the effects of a new ‘atypical’ antidepressant on the 
modulation of histamine and serotonin (Chapter 6). An outline of this dissertation is 
described below: 
Chapter 1: Introduction 
Chapter 2: Review of methods for neurochemical analysis in the brain.  
Chapter 3: This chapter describes the voltammetric investigation of the histaminergic 
system. I pharmacologically challenged receptors, synthesis, packaging, and metabolism 
of histamine to determine how synaptic histamine responds in male and female mice. 
Additionally, I investigated histamine release throughout the estrous cycle of female mice 
and sexual differences in H3R targeting drugs.  
Chapter 4: This chapter builds upon previous work that investigated the transport 
mechanisms of histamine. We determined SERT, NET, and OCT may all play a role in 
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histamine uptake. I used a genetically altered mouse model (Met172) with a SERT that is 
insensitive to certain SSRIs to rule out SERT’s contribution to histamine uptake. 
Chapter 5: This chapter covers the application of histamine FSCV to an animal model of 
inflammation. I analyzed the evocable histamine levels in behaviorally depressed mice 
(chronic mild stress paradigm) and compared that to age matched controls. 
Chapter 6: This chapter describes the response of histamine and its modulation of 
serotonin in response to a new ‘atypical’ antidepressant, ketamine. Ketamine doesn’t 
directly target the monoaminergic systems like traditional antidepressants (eg. SSRIs). I 
found that ketamine caused a rapid and sustained inhibition of stimulated histamine release 
and greatly alleviates the inhibition of serotonin levels in the posterior hypothalamus. 
Chapter 7: The final chapter summarizes the conclusions of my work and highlights future 
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 This chapter focuses on analytical detection methods for measuring 
neurotransmitters in vivo. The discussion begins by outlining the challenges of in vivo 
neurotransmitter analysis. Then, microdialysis, an in vivo sampling method, is critically 
described. Subsequently, three methods of direct detection of neurotransmitters are 
presented in terms of their advantages and disadvantages. Finally, future directions of 
monitoring brain chemistry are prospectively explored. 
2.1 Introduction 
Neurotransmission is the essential mechanism via which brain cells communicate. 
This process is fundamental to all aspects of brain function. Briefly, biochemical impulses 
arrive at the initiating, or presynaptic, cell that cause neurotransmitter-filled vesicles to fuse 
with the cell’s membrane. The neurotransmitter contents of these vesicles are then expelled 
into the small gap preceding the receiving or postsynaptic cell, called the synapse. The 
neurotransmitter then interacts with a postsynaptic protein (receptor), relaying the 
biochemical message from the presynaptic cell via initiation of a signaling cascade. The 
neurotransmitter is subsequently inactivated in the synapse either through reuptake back 
into the presynaptic cell via transporter proteins and/or enzymatic catabolism directly in 
the synapse. This process is fast (sub-second), the levels of transmitters are low in the 
extracellular space (nanomolar) and the synaptic space is tight (nanometers). Taken 
together, these characteristics immediately render an investigation of neurotransmission a 
difficult analytical challenge. 
Meaningful analytical measurements of neurotransmitters are highly significant, 
since there is a clear gap in the understanding of the chemical underpinnings of brain 
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pathophysiology. This shortcoming makes it almost impossible to accurately diagnose and 
treat disorders of the brain. A clearer definition of the roles of neurotransmitters in health 
and disease would greatly enhance the ability to improve diagnostic and therapeutic 
approaches to the brain. 
Analytical chemists have developed a suite of tools for analysis of the low 
concentration of neurotransmitters within the dynamic and harsh environment of the brain. 
Each method possesses inherent advantages and shortcomings. This module represents an 
overview of cutting-edge analytical approaches for neurotransmitters. The discussion 
begins with an outline of the analytical challenges for monitoring neurotransmitters. Two 
major classes of analytical methods, microdialysis, an in vivo sampling technique, and 
direct detection at microelectrodes, are highlighted in the context of their pros and cons. 
While the majority of work cited focuses on in vivo analysis, we chose to include work on 
single cell exocytosis. We believe there is much value in understanding fundamental 
mechanisms of neurotransmitter function via these single cell models. Cutting-edge 
advances in development or applications of these methods are showcased. Finally, the 
future of neuro-analytical chemistry is prospectively discussed. 
2.2 Analytical Challenges for Measuring Neurotransmitters 
Neurotransmission occurs as a function of many simultaneous processes that 
control extracellular neurotransmitter levels. To characterize the chemistry of 
neurotransmission, ideally two types of measurements are necessary. First, is the ambient 
extracellular neurotransmitter concentrations that depict the system at rest. Second, is the 
much faster, neurotransmitter release and reuptake events that define receptor, transporter 
 
 20 
and catabolic activity. In the proceeding text we refer to these measurements as slow and 
fast measurements. 
While slow and fast chemical measurements of neurotransmitters are the targets of 
analysis, there are several, chemical and non-chemical, criteria that need to be addressed 
for successful neuro-analytical measurements. These criteria are discussed below. 
2.2.1 Biocompatibility 
Chemical measurements, for the most part, involve direct implantation of a probe 
into the tissue. Implantation of foreign objects into the brain cause rapid and severe immune 
responses that serve to isolate the object from surrounding tissue.1-2 This renders 
electrochemical measurements during immune attack very challenging.  
Metal substrates, such as Ag and Pt, are excellent laboratory probes because they 
are inert. However, these materials are not ideal for implantation into the brain because of 
a robust immune response arising primarily because Ag or Pt are not readily found in 
mammalian bodies.3-4 
One strategy being explored to alleviate the immune response occurring from 
implantation is the controlled release of therapeutic compounds through polymer coatings. 
For example, the Schoenfisch lab at the University of North Carolina has been developing 
methods to control the release of nitric oxide, an immune mediator, from polyurethane 
coated glucose biosensors.5-7 Another approach is to utilize a fundamentally biocompatible 
material, which the body does not immediately perceive as foreign. A good example of this 
is carbon. Carbon has been shown to be biocompatible and maintain its measurement 
capabilities over days to weeks.8 This material has been fashioned into innumerable forms, 
the most popular of which in neuroanalysis are carbon fiber electrodes.9-10 Furthermore, 
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carbon electrode surfaces can easily be manipulated with polymer coatings or structural 
moieties (e.g. carbon nanotubes and nanotube yarns) to increase selectivity to a specific 
analyte.11-15 
2.2.2 Invasiveness 
Damage created by insertion of a probe is a profound consideration. The distance 
through which neurotransmitters relay their biochemical messages are 10s of nanometers, 
thus, the measuring probe must retain its dimensions as small as possible. 
Capillaries are responsible for blood transport throughout the brain and create the 
blood-brain barrier via their connection with astrocytes. If the blood-brain barrier is 
compromised, brain homeostasis can be severely disrupted. The intercapillary distance 
dictates the size of probe that can be introduced into brain tissue without rupturing the 
blood-brain barrier. This distance varies between brain regions in rodents but does not 
exceed ~30 m.16-17 Intercapillary diameter is inextricably linked with the biocompatibility 
of a probe, as any material large enough to compromise the blood-brain barrier will induce 
an immune response. Therefore, microelectrodes with one dimension under ~30 m show 
the most promising outlook to qualify as minimally invasive. When met, the criteria of 
biocompatibility and minimal invasiveness allow for probes to remain in tissue for weeks 
or months without evidence of gliosis.8 Currently, sample methods are not typically able 
to employ < 30 m probes but the miniaturization of standard techniques like microdialysis 
is actively being pursued. One of the limiting factors in the size of microdialysis probes is 
the sample membranes are prefabricated. Decreasing probe size is limited by perfusate 
channels and reasonable flow rate. Microfabricated silicon microdialysis probes have been 
created with 70 µm x 85 µm and 45 µm x 180 µm thick sampling areas.18-19 While 
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microdialysis is limited in its size, the technique is widely applicable and recently a method 
has been developed to alleviate the inevitable penetration injury response. Retrodialysis 
with an anti-inflammatory compound, dexamethasone, has been shown to drastically 
reduce symptoms of probe damage.20 
2.2.3 Temporal Resolution 
To study slow vs. fast changes fundamentally different time scales are required. 
Slower shifts in ambient neurotransmitter levels can be captured with measurements every 
minute to 10s of minutes. However, the fast changes that correspond to transmission 
necessitate sub-second temporal resolution analysis. Of the methods surveyed below, 
microdialysis serves to provide information about slower ambient level shifts while fast 
voltammetric methods indicate the sub-second neurochemistry of the analyte. In recent 
years, however, fast voltammetric methods have been modified to provide ambient level 
information.21-23 
For exocytosis analysis, amperometric methods at single cells provide microsecond 
temporal resolution that resolves mechanistic information about exocytotic events.24-27 
2.2.4 Sensitivity and Selectivity 
Chemical messengers in the brain are present at very low concentrations, typically 
in the nanomolar to low micromolar range.21, 23, 28-29 Additionally, there are many 
structurally and chemically similar analytes (precursors and metabolites). Thus, a high 
degree of sensitivity and selectivity (i.e. the ability to discern between analytes) is 
necessary for neurotransmitter analysis. For sampling methods such as microdialysis these 
criteria are less of a challenge since the ability to prepare the sample ex-vivo provides many 
opportunities to improve sensitivity and selectivity. With direct analysis, however, it is 
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much more challenging to acquire both a high level of sensitivity and selectivity. Thus, 
most direct analysis is limited to one, at most, two analytes.12, 30-33 
2.3 Neurochemical Analysis Methods 
For the purposes of this section, we chose to breakdown neurotransmitter analysis 
into two main factions: 1) A technique based on sampling, followed by detection, namely 
microdialysis and 2) direct detection at microelectrodes. 
2.3.1 Microdialysis 
Microdialysis utilizes a probe that is implanted into brain tissue. This is a sampling 
method that uses a semi-permeable membrane to allow the selective diffusion of analytes 
into a collection stream, the dialysate. Microdialysis sampling can be used to study the 
effects of pharmacological agents on various endogenous systems or metabolism of the 
agents themselves. The method can also be utilized for delivery of pharmaceutical agents. 
Following sample collection, the dialysate is coupled to a secondary analysis system such 
as liquid chromatography - mass spectrometry34-37 or biosensors.38-40 A key advantage of 
microdialysis is its ability to monitor multiple analytes. 
2.3.1.1 Microdialysis Probes; Mitigating Tissue Damage and Immune Response 
Microdialysis probes are typically between 200 and 300 m in diameter, because 
recovery rate is directly proportional to porosity and surface area.18, 41-44 These dimensions 
cause significant damage to brain tissue.2, 45 This damage creates two primary issues; first, 
emanating from the probe is a concentric gradient of damaged cells extending around 250 
m46 and sampling from this compromised tissue confounds data.47 Secondly, 
microdialysis sampling devices greatly exceed the intercapillary distance in rodent brains 
(~30 µm). This means that when implanted into brain tissue, these probes damage blood 
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vessels, compromise the blood-brain barrier and induce a rapid inflammatory response. As 
such, profound gliosis has been observed around the microdialysis implantation site which 
reduces probe stability over time and impedes analyte diffusion into the dialysate stream.20, 
48-49 
To improve the integrity and longevity of microdialysis measurements, researchers 
have sought to a) mitigate the initial penetration damage via probe miniaturization and b) 
lessen the brain’s immune response to probe implantation. We briefly discuss these two 
strategies below: 
a) A good approach for reducing tissue damage caused by the microdialysis probe 
is to decrease the overall size. A significant dimension is the intercapillary 
diameter of ~30 µm in the mouse brain (vide supra). To this end, Kennedy and 
colleagues are miniaturizing microdialysis probes. For example, a silicon 
microdialysis probe (45 µm x 180 µm) was microfabricated with a nanoporous 
membrane embedded onto the probe that functions as the sampling 
membrane.18-19 A key disadvantage of probe miniaturization is the loss of 
recovery. At flow rates of 100 nL/min, Lee et al. only observed 2-21% recovery 
rates with the microfabricated silicon probe, which has been attributed to pore 
blockage.18 
b) To reduce the brain’s immune reaction to implanted probes, Michael and 
colleagues have shown that retrodialysis of an anti-inflammatory 
glucocorticoid, dexamethasone, greatly reduces glial scarring typically seen at 
microdialysis probe tracks.50-51 Without dexamethasone treatment, electrically 
evoked dopamine release was not observable in tissue ~100 m from probe 
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implantation nor at the dialysate outflow within 4 hours of implantation. 
However, following dexamethasone retrodialysis, dopamine release was 
restored in surrounding tissue and in the dialysate. Additionally, 
immunohistochemistry confirmed that dopamine transporters surrounding the 
probe track were preserved after dexamethasone treatment.51 Furthermore, 
beneficial effects were observed for up to 5 days after cessation of 
dexamethasone perfusion.49 
2.3.1.2 Improving the Temporal Resolution of Microdialysis 
Perfusion rates through the microdialysis probe must be slow enough (typically 1-
2 L min-1) to allow analytes to reach equilibrium with the solution inside the probe, 
facilitating sufficient recovery. This slow perfusion rate is one of the factors limiting the 
temporal resolution of microdialysis experiments to slower, ambient level changes, on the 
order of 10s of minutes.46, 52 Increasing the perfusion rate would provide better temporal 
resolution, however this strategy is a trade off with sensitivity since a faster rate of 
perfusion would mean less time for analyte diffusion into the probe. Innovative solutions 
to this tradeoff are discussed below. 
2.3.1.2.1 Liquid Chromatography Coupled to Electrochemical Detection 
Ngo et al. reported in vivo monitoring of striatal dopamine in awake-behaving rats 
with under one-minute resolution via on-line liquid chromatography coupled to 
electrochemical detection. To achieve this sub-minute analysis, a previous separation53 was 
modified by using an 8-port, 2-loop separation setup, increasing the sample volume from 
500 nL to 600 nL and decreasing HPLC flow rate from 9.0 L min-1 to 7.5 L min-1. This 
higher temporal resolution allowed a detailed view of the dopaminergic response to 
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pharmacological manipulation.47 In a similar progression of experiments, serotonin was 
measured at 1-3 minute time resolution.52, 54-56 
2.3.1.2.2 Microchip Electrophoresis 
An alternative method to rapidly analyze microdialysis samples is microchip 
electrophoresis.57-60 Microchip electrophoresis uses nL sample volumes and an applied 
electrical potential to separate analytes in dialysate that travels a series of conduits etched 
into a silicon-based wafer. Due to the small volume used and fast separation technique, 
microchip electrophoresis limits the band broadening of sample plugs.61 This approach has 
pushed the temporal resolution of microdialysis sampling to under 60 s62-63, reaching < 15 
s.64-67 In 2008, Wang et al. reported a microfluidic device that preserved sampling 
resolution via segmentation of the dialysate flow into nL droplets by introducing an 
immiscible oil.68 The oil partitioned the sample stream into discrete pockets that minimized 
band broadening while allowing for <15 s temporal resolution. Recently, segmented flow 
has been applied to measurements of acetylcholine69 and glutamine, glutamate and gamma-
aminobutyric acid, simultaneously via nano-electrospray ionization mass spectrometry 
with 6 second time resolution at 100 nL min-1.70 
2.3.1.2.3 Enzyme Biosensing 
Microdialysis has also been coupled to enzyme biosensing for rapid (30 s) analysis. 
An on-line rapid sampling microdialysis method was developed and applied to clinical 
microdialysate to visualize biochemical changes during patient surgery.40, 71 In 2018, the 
resolution of clinical dialysate that had been collected off-line was compared to on-line 
dialysate. Samples stored at -80°C for up to 72 days showed good time alignment with 
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samples collected on-line.38 A schematic of sampling from the brain to analysis by the 
biosensors is shown in Fig. 1 below. 
 
Figure 2.1: Continuous online microdialysis analysis system for bedside 
monitoring using microfluidic chips containing biosensors for glucose and 
lactate and a potassium ion selective electrode. (a) shows the overall setup. (b) 
Raw traces from glucose (red), potassium (purple) and lactate (green) during a 
computer-controlled three-point automatic calibration run. Concentrations 
indicated by legend. (c) Sequential analysis of sensor performance over 12 h 
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using automatic calibration. (d) Raw data for microdialysate brain lactate 
levels collected at the bedside with three automatic calibrations. The green 
boxes indicate sections of clinical data and the grey boxes indicate calibrations. 
Clinical data were collected from patient 2. Reproduced from Rogers, ML. et 
al. J. Cereb. Blood Flow Metab. 2017, 37 (5), 1883-1895. 
 
A method utilizing microdialysis sampling with on-line electrochemical detection 
for acetylcholine monitoring was reported by Lin et al. in 2015.39 Dialysate flowed through 
a bioreactor with choline oxidase and prussian blue immobilized onto iron nanoparticles. 
The enzyme-catalase pair removed choline (and subsequent peroxide) present in the 
dialysate thus ensuring accurate quantification of acetylcholine at the detector. 
2.3.2 Direct Detection of Neurotransmitters 
In the following section we outline three methods of direct neurotransmitter 
analysis: enzyme biosensors, amperometry, and fast-scan cyclic voltammetry (FSCV). The 
biosensor and FSCV studies included here measure in vivo neurotransmitter concentrations 
while the amperometry studies investigate exocytosis at single cells ex vivo. 
2.3.2.1 Biosensors 
Biosensors play a powerful role in the toolbox of neuro-analytical methods as they 
are capable of monitoring traditionally non-electroactive molecules. Biosensors are 
chemical detection platforms that produce a quantifiable signal proportional to a specific 
analyte following an enzymatic reaction at a sensor surface. 
The majority of biosensors designed for neurotransmitter analysis rely on oxidation 
of enzymatically generated hydrogen peroxide as a direct proxy of analyte concentration.72-
74 Inclusion of a size exclusion polymer is necessary to isolate the electrode surface from 
interferences while still allowing hydrogen peroxide diffusion. Two commonly used 
polymers are a Nafion-polypyrrole combination or 1,3-phenylenediamine.72-74 
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Microfabrication of biosensors produces microarray electrodes composed of multiple 
individual sensing sites on one ceramic substrate. A microarray of four electrodes can be 
isolated to create two enzyme sensors and two in situ control sensors.75 
There have been many biosensors created for a myriad of substrates since their 
introduction in the late 1960s76-79 Neurotransmitter biosensors utilize enzymes that are 
responsible for the endogenous break down of the analyte, i.e. glutamate oxidase for the 
metabolism of glutamate. These sensors often exhibit promising results in vitro but in vivo 
applications of biosensors in the brain are severely limited.1, 80-81 The two primary 
challenges for in vivo biosensing are a) biosensors are large (typically >300 µm) relative 
to brain tissue (see above for issues with large probes and neurotransmitter measurements) 
b) biosensors rely on immobilized enzymes which have poor stability. We next discuss 
these issues briefly. 
Biosensors are typically hundreds of microns in 2 or all 3 dimensions.82-85 
Furthermore, metals like platinum (Pt) often serve as the electrode platform. Both the large 
dimensions and presence of metals like Pt serve to trigger inflammation and gliosis around 
the implantation site, that creates analysis limitations as described above.86 This foreign 
body reaction dramatically reduces device stability. Two strategies are being explored to 
decrease the probe size and reduce local inflammation. First, the Sombers lab at NC State 
has been pioneering the immobilization of glucose oxidase onto carbon fiber 
microelectrodes for successful in vivo glucose measurements.87 The probe that is utilized 
has a substantially smaller footprint than traditional biosensors at 25 m diameter and 100 
m length. These probes were further optimized to simultaneously detect glucose and 
dopamine.88 Second, the Schoenfisch lab at UNC are on the forefront of increasing the 
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longevity of in vivo placement of biosensors by applying nitric oxide releasing polymers. 
There are analytical challenges associated with nitric oxide loading into polymers, 
undesired leaching over time and controlling the release parameters of the polyurethane 
coating.7, 89 Despite current working challenges, this technique has shown promising results 
in swine in vivo implantation for several days.5-6 
Enzymes have a small window of efficiency in which they best function. Enzyme 
activity drops off exponentially when the it is not in conditions that mimic the enzyme’s 
ambient environment (e.g. temperature and pH). This means pre- and post-
calibrations/preparations likely denature enzymes and reduce probe activity. Moreover, 
enzyme loading on the electrode is a balancing act; a high load is necessary for adequate 
response. However, this comes at the expense of production of high concentrations of 
metabolic products of analysis (e.g. hydrogen peroxide) that inhibit and/or denature the 
enzyme. Ongoing work is to optimize this balance.90-92 
2.3.2.1.1 In Vivo Measurements 
As stated above, direct in vivo analysis with biosensors is limited. In the past five 
years there are a handful of studies that have been successful in vivo. Measurements of 
glutamate are common. In the rat cortex, studies have been carried out using a platinum 
electrode array to reveal acetylcholine and kynurenic acid’s dependence on glutamate 
release.73, 93 A new glutamate sensor that benefits from sensing platforms on each side of 
the ceramic substrate was reported for investigating distinct areas of the brain 
simultaneously.94 Glutamate release has also been monitored in the nucleus accumbens and 
ventral tegmental are in rats using a commercially available glutamate oxidase coated Pt-
Ir wire, 180 m diameter.95 Malvaez et al. were able to demonstrate that glutamate release 
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in the basolateral amygdala encodes outcome-specific motivation.74 Outside of glutamate, 
an enzyme-linked microelectrode array was reported for the detection of adenosine in the 
rat cerebral cortex.96 The effects of learned behavior and cue detection on acetylcholine 
transients have been analyzed in the rat frontal cortex using a Pt electrode with immobilized 
acetylcholinesterase and choline oxidase embedded on a ceramic substrate, similar in 
fabrication to the glutamate sensors detailed above.97-98 
2.3.2.2 Amperometry 
Although the methods discussed in this module focus on the in vivo detection of 
neurotransmitters, we chose to include this section on amperometric detection of single cell 
vesicular events (ex vivo) because of the fundamental importance exocytotic events play in 
understanding the mechanisms of neurotransmission. 
Exocytosis, the process by which neurotransmitter-filled vesicles fuse with and 
expel their contents out of the cell, is a primary mechanistic player in neurotransmission. 
Understanding exocytosis in terms of fusion pore size, duration, and the amount of content 
released during fusion is critically important to neurotransmission studies. When applied 
to single cell measurements at carbon microdisc electrodes, amperometry is a unique 
technique to investigate the release dynamics of exocytosis. This is because in 
amperometry an electrochemical potential is applied to the electrode and held at a constant 
value thus sampling frequency can be very high and time resolution can be on the order of 
microseconds. 
2.3.2.2.1 Electrode Platforms; Carbon Disc, Short Cylinders, & Microelectrode Arrays 
Carbon discs are the most common platform on which to perform single cell 
amperometry.99 These disc electrodes are fabricated by filling a glass capillary a single 
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carbon fiber and then pulling the capillary apart under heat and gravity to form a carbon-
glass seal. To form the disc shape, the microelectrode is beveled at a 45-degree angle. 
Oftentimes, to reinforce the carbon-glass seal, a small application of epoxy resin is applied 
to the electrode before experimentation. Despite variations among individual carbon fibers, 
it was found that factors such as charge and maximum current were independent of surface 
area and remained constant for disc electrodes made with 7 m fibers.100 Surface 
modification of carbon discs to increase sensitivity is ongoing.101 
Although most amperometry at cells utilizes carbon discs, carbon fibers are also 
employed, although they tend to be etched to decrease their size. The cylindrical shape 
enables insertion into the cell to monitor intracellular chemistry. Cylinders can also be used 
for vesicle impact electrochemical cytometry (VIEC).102 VIEC utilizes the immediate 
interaction of vesicle and carbon surface to explore direct vesicle release processes. VIEC 
has been used to model the vesicle membrane fusion and pore opening of PC12 cells103 as 
well as modeling the percentage of vesicle content oxidized with respect to cell location on 
the electrode surface.104 
Application of similarly designed carbon microelectrode arrays of 2, 3, and 7 disc 
electrodes were used to improve spatial and temporal resolution of cellular exocytosis 
measurements.105 Electrode tips were spaced 7 m apart, which demonstrated the ability 
to resolve simultaneous release events. Electrode crosstalk was analyzed for fast-scan 
cyclic voltammetric and amperometric detection using a 7-disc microarray.106 Crosstalk 
was minimal for amperometric detection because amperometric reactions occur rapidly. 
By contrast, oxidative processes measured with FSCV (described below) are slower since 
analysis involves redox cycling. Here, molecules can diffuse to adjacent electrodes 
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permitting substantial crosstalk. A 30 m x 30 m microelectrode array with 36 2-m-
width microelectrodes was fabricated via photolithography. Cells were adhered to the 
surface to spatially analyze the heterogeneity of exocytosis.107 
 
Figure 2.2: Vesicle impact electrochemical cytometry. (A) Optical micrograph of the 
experimental setup for exocytosis. Scale bar: 20 μm. Detection of exocytosis was carried 
out by applying 700 mV (versus Ag/AgCl reference electrode) to the electrode. (B) Scheme 
to show the different parameters for event analysis. Reprinted (adapted) with permission 
from Ye, D., Gu, C., Ewing, A. ACS Chem. Neurosci. 2018, 9(12), 2941-2947. Copyright 
2018 American Chemical Society. 
 
2.3.2.2.1 Key Studies in the Mechanisms of Exocytosis 
An ongoing debate on the key mechanisms of vesicular release continues to date.26 
Dynamin, an enzyme involved in the late stages of endocytosis, has been shown to have 
contrasting effects during exocytosis, namely being necessary in stabilizing the fusion pore 
and increasing fusion duration.108 When dynamin was inhibited, a shorter release duration 
and smaller pore size were observed supporting proposed the ‘kiss-and-run’ hypothesis.108 
Additionally, there is evidence that inhibiting actin, a transport mediating polymer, 
influences the closing mechanisms of pore fusion and results in larger pore size and 
fractional release supporting the ‘kiss-and-run’ hypothesis of release.109 Alpha-synuclein, 
a protein localized at nerve endings, was shown to increase fusion duration reducing ‘kiss-
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and-run’ characteristics pointing towards partial release fusion dynamics as being the 
normal function.110 Experimental and mathematically modeled exocytosis provided 
evidence that fusion pores do not exceed ⅕ of the radius of the vesicle, strongly detracting 
the notion of full fusion.111 Recently, Ye et al. showed mechanistic evidence of pore size 
and fusion duration fluctuations may explain the neuroprotective and neurotoxic effects of 
lidocaine.27 
Evidence of full vesicle fusion has been shown to be dependent on cell membrane 
tension where, amperometric and imaging data revealed that both partial release and full 
fusion were found to occur.112 
2.3.3 Fast-Scan Cyclic Voltammetry 
FSCV at carbon fiber microelectrodes (CFMs) can directly, electrochemically 
measure certain electroactive analytes with sub-second temporal resolution. 
2.3.3.1 Carbon Fiber Microelectrodes 
Carbon fiber microelectrodes (CFMs) are most often used when applying FSCV to 
the detection of neurotransmitters for their excellent biocompatibility and electroactive 
surface and their small size. Typical CFMs used in FSCV experiments are ~7 m in 
diameter and range in length from 20-150 m and benefit from small sampling areas, or 
‘hot spots’ of neuronal activity. 
Carbon has a wide-ranging chemical reactivity that allows for numerous paths to 
surface modification. Stable polymer deposition has been achieved.11, 13 Scanning to high 
positive potential limits has been shown to increase surface oxide density and adsorptive 




2.3.3.2 Scan Rate 
FSCV utilizes fast scan rates (400 - 1000 V s-1) to detect fast changes in 
neurotransmitters. The electrical double layer at the CFMs charges and discharges, like a 
capacitor, into the electrode. At high scan rates, this ‘charging current’ is much larger in 
amplitude than the Faradaic processes that define neurotransmitter redox reactions. Thus, 
FSCV is background subtracted to remove the background charging or capacitive current. 
As different species adsorb to the CFM, the charge and discharge profile of the double 
layer capacitor changes and as such, this current cannot be subtracted out, appearing on 
FSCV color plots (raw data) as narrow peaks at switching potentials. Switching peaks 
cannot be easily be utilized to identify substrates since any adsorbed species on the CFM 
can create a switching peak. Thus, there has been significant efforts to remove this 
erroneous signal.118 
2.3.3.3 Waveforms 
The waveform is an integral part of FSCV analysis. A waveform is the combination 
of 2 or more linear voltammetric sweeps and a set of instructions that dictates how the 
potential changes with time at the electrode. Waveforms have been modified to increase 
the selectivity of analyte detection based on electrostatic and electron transfer differences 
between analytes. Commonly used FSCV waveforms are illustrated in Figure 2.3 below. 
2.3.3.4 Ambient Neurotransmitter Measurements with FSCAV 
Because FSCV is background subtracted, it is necessary to induce a change in 
neurotransmitter concentration, this has been achieved electrically119, 
pharmacologically120, and optically.121 Thus, the baseline, or ambient level concentrations, 
are unknown with FSCV recordings. This was, for decades, a key disadvantage of the 
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method. A great deal of information can be garnered from ambient level neurotransmitter 
measurements concentrations. 
 
Figure 2.3: Outline of current FSCV waveforms for various species and any 
modifications to the CFM. 
 
In 2013 Atcherley et al. introduced a method to quantify the absolute concentrations 
of dopamine at CFMs utilizing a FSCV-like technique that relies on waveform selectivity 
and a controlled adsorption step.22 This method, fast-scan controlled-adsorption 
voltammetry (FSCAV), represents a significant analytical breakthrough for the field of 
voltammetric monitoring of neurotransmitters.23 Pairing FSCV and FSCAV analysis 
enables a researcher to elucidate both the fast and slow chemical changes that define 
neurotransmission. Briefly, a dopamine-specific waveform is applied to the electrode, but 
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at a high enough frequency (100 Hz) that dopamine adsorption to the electrode is 
minimized. The waveform is then ‘switched off’ and a constant potential is applied instead 
for 5-15 seconds to allow dopamine to come to an adsorption equilibrium on the electrode 
surface. The dopamine waveform is then reapplied, resulting in rapid oxidation/reduction 
of the adsorbed dopamine, essentially quantifying the ambient dopamine surrounding the 
CFM. FSCAV was expanded to ambient serotonin measurements in 2017 by Abdalla et al. 
with slight modifications to the electrode surface, specifically, electrodeposition of Nafion 
prior to the experiment.21 
 
Figure 2.4: Serotonin FSCAV (A) Representative FSCV (i) and FSCAV 
(ii) color plots of 100 nM serotonin in vitro. (B) Cyclic voltammograms 
extracted from the vertical dashed lines in A(i) and A(ii) after normalization 
(current/maximum current). Vertical orange dashed lines represent 
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integration limits. Reprinted (adapted) with permission from Abdalla, A. et 
al. Anal. Chem. 2017, 89 (18), 9703-9711. Copyright 2017 American 
Chemical Society. 
 
2.3.3.5 Chronically Implanted Electrodes 
Typical FSCV experiments will last 3-8 hours with an acutely implanted electrode. 
Uncertainties regarding the long-term stability of and the foreign body reaction to 
chronically implanted microelectrodes were eased in 2010 when the Phillips lab reported 
stability and minimal tissue disruption, confirmed by immunohistochemical staining, up to 
four months post-implantation of a CFM.8 Chronically implanted CFMs have also be 
applied to awake-behaving studies of non-human primates with successful detection 
occurring up to 100 days post-implantation.122 A key feature to highlight is the fact that 
CFMs renew their surface when the applied potential is sufficiently high to oxidize carbon 
(i.e. >1.1 V vs Ag/AgCl). While this method likely contributes to long term stability in 
response, long-term waveform application may steadily etch the carbon electrode, 
decreasing the overall size of the electrode and compromising the carbon-glass seal.115 
2.3.3.6 Expanding Beyond Dopamine; Increasing the Scope of FSCV 
For several decades, in vivo FSCV measurements were limited to dopamine. A serotonin 
selective waveform was established in 1995123 and optimized with electrode modification 
in 2009 for selective in vivo serotonin analysis in rats.11 Two factors were crucial for the 
optimization of in vivo serotonin FSCV. First, a thin layer of Nafion, a cation exchange 
polymer, is necessary to block the electrode fouling effects of serotonin metabolites. 
Second, a high scan rate (1000 Vs-1) exploits the more favorable electron transfer kinetics 
for serotonin redox reactions vs. dopamine, enabling more sensitivity towards serotonin. 
In vivo serotonin FSCV has revealed evidence of dual transport mechanisms in the 
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serotonin synapse and discrete circuitry dependent on sublayer morphology within the 
medial prefrontal cortex.124-125 
 
Figure 2.5: Met-enkephalin FSCV (A) Triangular waveform (TW). (B) 
Modified sawhorse waveform (MSW). (C, D) Representative in vitro 
voltammetric data collected using the waveforms depicted in parts A and B, 
respectively, where the ordinate is the potential applied to the carbon-fiber 
electrode, the abscissa is time in seconds, and the current (nA) is depicted in 
false color. 2 μM M-ENK was introduced to the microelectrode at the time 
indicated by the red bar. Displayed voltammograms were extracted at the 
time indicated by the dashed line. Asterisks indicate electrode fouling. 
Reprinted (adapted) with permission from Schmidt, AC. et al. Anal. Chem. 
2014, 86 (15), 7806-7812. Copyright 2014 American Chemical Society. 
 
 Fast-scan cyclic voltammetry has been expanded to include hydrogen peroxide126-
127, adenosine12, 117, octopamine128, tyramine129, histamine130, norepinephrine131-132, 




Figure 2.6: Melatonin fouls the surface of the carbon-fiber microelectrode using the 
traditional FSCV waveform. The traditional waveform for FSCV detection is defined 
as a −0.4 V holding potential scanned to 1.3 V switching potential and back at a rate 
of 400 V/s and 10 Hz frequency (A). A three-dimensional color plot represents the 
change in current as a function of both voltage and time. Melatonin (5 μM) is 
manually injected at approximately 5 s and washed away at approximately 10 s 
(denoted by blue arrows). For the traditional waveform, a secondary oxidation 
product remains even after melatonin has been flushed away by buffer. The CV for 
melatonin is not stable over time (i–iv). (B) A waveform for melatonin that 
eliminates fouling at the electrode surface is shown (0.2 to 1.3 V at 600 V/s). CVs 
remain stable during the length of the injection (i–iii) and are not present after the 
analyte was washed away (iv). Reprinted (adapted) with permission from Hensley, 
AL., Colley, AR., Ross, AE. Anal. Chem. 2018, 90 (14), 8642-8650. Copyright 2018 
American Chemical Society. 
 
Another key disadvantage of FSCV is that it is traditionally limited to detection of 
individual analytes. Simultaneous detection of dopamine and oxygen in anesthetized rats 
was reported in the early 1990s133-134 while simultaneous dopamine and glucose detection 
was recently reported.88 The approach of multi-monitoring has been applied to studies of 
oxygen and dopamine changes in response to spreading depolarization.31 In 2016 
Samaranayake and colleagues published a report detailing pharmacological and 
mathematical evidence of histaminergic modulation of serotonin in the mouse 
hypothalamus.32 FSCV’s fast measurements captured an increase in the concentration of 
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extracellular histamine coincided with a decreased release of serotonin. Evidence pointed 
towards activation of H3 receptors on presynaptic serotonin terminals functioning as a 
negative feedback loop to inhibit serotonin release. From this study, it is clear that 
expanding the ability of FSCV to monitor multiple analytes simultaneously can resolve 
questions surrounding the interaction of neurotransmitters in the synaptic area. 
Appreciating the connection of neurotransmitters can be used to better design and 
understand therapeutic effects of drugs. 
 
Figure 2.7: Histamine FSCV. (ai & aii) The position of electrodes (stimulation and 
carbon fiber microelectrodes) in the mouse brain. (bi & bii) Representative color 
plots of the stimulated release of histamine and serotonin in the premammillary 
nucleus (PM) and stimulated release of serotonin in the substantia nigra pars 
reticulata (SNr), respectively. (ci & ii) Superimposed cyclic voltammograms of in 
vivo and in vitro histamine and serotonin signals taken from vertical dashed lines in 
the PM. (ciii) Comparison of normalized cyclic voltammograms of in vivo serotonin 
signals taken from vertical dashed lines in both PM and SNr. HA, histamine; 5‐HT, 
serotonin. Reprinted with permission from Samaranayake, S., et al. J. Neurochem. 




FSCV instrumentation has long been sourced from prominent academic labs, 
whose electronics facilities assemble systems (e.g., University of North Carolina’s UEI 
potentiostat, University of Washington’s FSCV system, etc.). Limited technical and 
customer support, long purchasing lead times, and significant costs involved with such 
academic systems led to the emergence of commercial FSCV instrumentation options (e.g., 
Pine Research Instrumentation WaveNeuro, Pinnacle Technologies, Inc.), which have 
supported growth in the area of electroanalytical neurochemistry. The Dagan Corporation 
is an additional supplier of FSCV potentiostats as well. 
Data analysis software is available from several commercial or academic entities. 
Pinnacle Technologies, Inc. includes their FSCV software package with purchase of a 
system. The HDCV software package can be purchased from UNC at Chapel Hill, the 
WCCV software package can be purchased from Knowmad Technologies, LLC (Tuscon, 
AZ) or the Demon Voltammetry & Analysis software suite is freely available to academics 
and non-profits. (Wake Forest) 
2.4 Prospects and Conclusions 
Analytical neurotransmitter measurements is a thriving and cutting-edge field. 
Conventional limits of microdialysis are continuing to be pushed further to allow for less 
invasive, faster, more efficient sampling and separation methods. Decreasing the footprint 
of microdialysis probes through microfabrication will allow for more reliable sampling 
from intact tissue. With the increasing body of work demonstrating the advantages of 
locally perfusing anti-inflammatory agents, the field of microdialysis sampling, as a whole, 
stands to benefit from adopting this method. Along with smaller membranes, the resolution 
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of microdialysis is now steadily under the one-minute mark for on-line analysis with some 
methods reaching single second resolution. The trend is expected to continue with the 
joining of efficient microfabricated probes and single-second on-line detection. 
Recent developments in biosensor technology have explored the use of substrate 
anchored aptamers for the selective detection of molecules. Aptamers are short chained 
single stranded DNA or RNA that have a unique 3D conformation. They are synthetically 
produced and can therefore be tailor-made for various molecules. DNA based aptamer 
sensors that selectively bound to dopamine have been explored for their applications in 
dopamine monitoring.136-137 Additionally, the Andrews lab at UCLA has been exploring 
the use of DNA aptamer-based sensors for dopamine138 and have been expanding the 
applicability by detecting glucose, serotonin and dopamine in mouse serum with tailor-
made field-effect transistors.139 
A new class of multimodal monitoring has recently emerged as a promising method 
to stimulate and monitor numerous processes simultaneously. In a 2017 Nature 
Neuroscience report, Park and colleagues described a miniature device consisting of six 
individual electrodes, two microfluidic channels and a fiber optic channel for 
photostimulation.140 In vivo proof of concept was demonstrated by implantation in the 
medial prefrontal cortex of a mouse. There, viral injections were delivered through the 
device’s microfluidic channels followed by photostimulation and electrophysiology 
recordings. This device demonstrated favorable chronic stability in awake-behaving mice. 
Additionally, Patriarchi and colleagues introduced a novel fluorescence intensity-based 
genetically encoded dopamine indicator coined “dLight1.”141 Transfection of a viral 
protein into the striatum permitted two-photon imaging of dopamine response to an 
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electrical stimulation and cocaine challenge in slice preparations in addition to 
optogenetically stimulated dopamine release. Fluorescence data were also collected from 
awake-behaving mice in response to pharmacological administration and visuomotor 
learning tasks. Multimodal monitoring represents a substantial advancement in the field of 
neuroanalysis and the growing field of optogenetics. 
Recently a novel method has been developed, by Mei Shen’s group, to detect non-
electroactive neurotransmitters that utilizes ionic transfer across an immiscible liquid-
liquid interface (ITIES).142 A nanopipet filled with 1,2-dichloroethane was submerged into 
an aqueous solution of acetylcholine, tyramine, and serotonin. Electrodes placed in each 
phase allows the interface to function as the working electrode (WE). A voltammetric 
sweep is applied to one of the electrodes that can detect ionic transfer when charged 
molecules are polarized and cross the interface (WE). This method was applied to the 
detection of gamma-aminobutyric acid (GABA) in aqueous solution in 2018 with slight 
modification.143 Due to GABA being neutral at pH ~ 7, it required the addition of octanoic 
acid in the organic phase (nanopipet filling) to facilitate transfer of GABA through the 
liquid-liquid interface. Linear current increases were shown for serial additions of GABA 
concentrations for a small range. However, these experiments show the exciting first steps 
of a new analytical strategy to quantify non-electroactive neurotransmitters in aqueous 
solutions. 
Single cell amperometric recordings of exocytosis appears to be focusing on a 
consensus of ‘kiss-and-run’ release as being the main or only method of release. 
Investigations of proteins regulating the fusion pore size will continue to shed light on 
possible reasons for impaired neurotransmission during neurodegenerative disease and 
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other psychiatric disorders. Vesicle impact electrochemical cytometry and microelectrode 
arrays are essential tools for investigating intracellular vesicle dynamics and heterogeneous 
exocytotic events, respectively. 
 
Figure 2.8: Newly introduced detection mechanism based on pH 
modulation from an organic acid in the oil phase. This mechanism enables 
the direct electrochemical detection of γ-aminobutyric acid (GABA), an 
important neurotransmitter and a zwitterion, with nanoITIES pipet 
electrodes. Chemical structures of GABA at pH ≈ 7 (a) and pH ≈ 3 (b). The 
pKa of the amine and carboxylic acid moieties of GABA are 10.22 and 4.53, 
respectively. Without organic acid modulation, GABA is not detected; in 
contrast, after adding an organic acid, octanoic acid, to the oil phase 
contained inside the pipet, GABA is detected (c). Reprinted (adapted) with 
permission from Iwai, NT., et al. Anal. Chem. 2018, 90 (5), 3067-3072. 
Copyright 2018 American Chemical Society. 
 
FSCV continues to be a leading method for neurotransmitter analysis in the quality 
and accuracy of data it delivers. The scope and quantity of analytes are continually being 
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improved. Additionally, new brain regions are being explored as they are implicated in 
emerging disease states. We anticipate in vivo monitoring of trace metals with FSCV in the 
very near future. Trace metals, such as Cu2+, act as important cofactors in several synaptic 
processes and will help create a more thorough understanding of neurotransmission. FSCV 
analysis will continue to play a foundational role in determining the synaptic underpinnings 
of neurotransmitter regulation. 
In conclusion, a clear gap persists in understanding the fundamental chemistry of 
the brain with emphasis placed on obtaining meaningful analytical measurements of 
neurotransmitters. Targeted brain diagnoses and therapeutics are very difficult without 
these paired measurements. Understanding the role and function of neurotransmitters in 
healthy and diseased states would serve to greatly improve approaches to clinical treatment.  
This module served to outline the most recent, cutting edge analytical 
advancements in neurotransmitter analysis spanning primarily the last five years. There is 
a rich literature of important developments and applications for monitoring molecules in 
neuroscience. The discussion began with an outline of the analytical challenges 
encountered when monitoring neurotransmitters. Two major classes of analytical methods, 
in vivo microdialysis sampling and direct detection at microelectrodes, were highlighted 
with their respective advantages and disadvantages. Cutting edge advancements, 
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Histamine is an important molecule that plays a key role mediating inflammation 
throughout the body. In the central nervous system (CNS), histamine has a demonstrated 
ability to function as a neuromodulator. Historically, a substantial amount of 
pharmacological testing was carried out using only male animal models, however, in 2015 
the National Institutes of Health mandated that sex be included as a biological variable. 
Histamine remains understudied in the CNS especially with respect to how the male and 
female histaminergic systems respond to pharmacological treatments. In this chapter, we 
first compare the male and female systems and the influence the estrous cycle has on the 
histamine system under control conditions. Next, we target histamine receptors, vesicular 
packaging, synthesis, and histamine metabolism to explore differences between the sexes. 
We found robust similarities between male and female evoked histamine levels and no 
difference throughout the estrous cycle. Additionally, we found similar responses across 
sexes regarding receptors H1 and H2 antagonism, inhibition of vesicular packaging, and 
inhibition of synthesis and metabolism. Our data revealed that sex should be considered 
when evaluating the effectiveness of H3 targeting compounds as antagonism via 
thioperamide did not elevate histamine levels above control in female mice, even when 
pretreated with an H3 agonist to first decrease histamine. We posit that cycling hormones 
in pre-menopausal females provide a crucial anti-inflammatory role and regulate histamine 
levels in the brain as an evolutionary trait. Our study demonstrates the highly conserved 
nature of neurological systems and will aid in designing therapeutic strategies for both male 




Histamine is a biological amine with a well-established role in mediating 
inflammation, found in immune cells including glia1, mast cells2-3, and T-cells.4 In addition 
to its roles in the immune system, histamine has also been identified as a neuromodulator.1, 
5 In the central nervous system, histamine cells bodies reside in the tuberomammillary 
nucleus (TMN) with projections that innervate throughout the brain.6-8 Studies have shown 
that histamine is able to modulate the release of other neurotransmitters such as serotonin, 
dopamine, acetylcholine, glutamate and GABA.5 The majority of previous literature has 
been based on experimentation of male animal models (typically mouse or rat) and that 
data is then extrapolated to female models assumed to behave and respond in sufficiently 
similar ways. In 2015, the NIH mandated that all animal-based experiments carried out 
under their funding would have to consider sex as a biological variable.9 Differences in the 
peripheral histamine systems of male and female mice have been shown,10-11 along with 
previous suggestions that histamine may be present at higher basal levels in females.12-14 
Additionally, hypothalamic concentrations of histamine and its associated enzymes are 
found to vary through the estrous cycle.15-18 However, due to the difficulties with 
measuring histamine in the brain, there is a clear lack of information regarding central 
histamine chemistry between the sexes and if peripheral histamine relates to central. 
CNS histamine has been previously studied using brain homogenates15, 19, in vivo 
microdialysis coupled to high-performance liquid chromatography20-21, and 
electrophysiology.22-23 More recently, the Hashemi lab developed a fast-scan cyclic 
voltammetry (FSCV) method to selectively detect histamine in vivo.24-25 The power of our 
technique is that it creates minimal inflammatory response and directly measures both 
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histamine and serotonin at a single carbon fiber microelectrode (CFM).24 We showed that 
evoked histamine resulted in an inhibition of serotonin release due to H3 receptors present 
on 5-HT terminals; this data was in agreement with previous findings.26-27 
In this study we investigated potential sex differences of the central histaminergic 
system between male and female. We first use FSCV to characterize the release and 
reuptake characteristics of histamine release of both sexes and the effects of this release on 
serotonin under control conditions. We then compared the evoked release of histamine 
throughout the four stages of the mouse estrous cycle, namely estrus, metestrus, diestrus, 
and proestrus. Next, an extensive pharmacological screening is undertaken to target 
histamine receptors H1R, H2R, H3R, H4R, histamine synthesis, vesicular packaging, and 
metabolism in both male and female mice and compare the effects of each. Interestingly, 
the only significant differences we find were when targeting H3R in females, leading us to 
explore the possibility of cycling hormones playing a key role in the female mouse’s ability 
to mitigate immunologic signaling. Finally, we compared the release and reuptake profiles 
of stimulated histamine with electrode placement in the posterior hypothalamus and found 
that regions receiving significant input from hormones, (i.e. ventromedial nucleus) are 
more likely to have variable profiles. This study provides broad insight into the 
histaminergic system of male and female mice and will yield better understanding of how 
an understudied neurochemical system functions. 
3.2 Materials and Methods 
Chemicals and Reagents 
 All chemicals were used as received from the supplier. Diphenhydramine 
hydrochloride (20 mg kg-1; Sigma Aldrich, St. Louis, MO, USA), zolantidine dimaleate 
 
 51 
(10 mg kg-1; Tocris, Minneapolis, MN, USA), immepip dihydrobromide (5 mg kg-1; Sigma 
Aldrich), thioperamide maleate (20 mg kg-1 or 50 mg kg-1; Sigma Aldrich and Tocris), 
tacrine hydrochloride (2 mg kg-1; Tocris), and α-fluoromethylhistidine (20 mg kg-1; 
Toronto Research Chemicals, North York, ON, CAN) were all dissolved in sterile saline 
(0.9% NaCl solution, Mountainside Medical Equipment, NY, USA) at 5 mL kg-1. 
Reserpine (10 mg kg-1; Sigma Aldrich) was dissolved in 0.1 % acetic acid (Sigma Aldrich) 
in sterile saline at 5 mL kg-1. Tetrabenazine (Sigma Aldrich) was dissolved in 10 % DMSO 
(Sigma Aldrich) in sterile saline with 1 M HCl (10 µL mL-1 injection volume). All solutions 
were made fresh at the time of injection and all injections were given via intraperitoneal 
(ip) injection. Urethane (Sigma Aldrich) was dissolved in sterile saline as a 25 % w/v 
solution and administered at 7 µL kg-1.  
Electrode Fabrication 
All electrodes are made in house. A single carbon fiber is aspirated into a 
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim 
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige, 
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is trimmed 
under light microscope to ~150 µm by scalpel. An electrical connection is forged with the 
fiber through a stainless-steel connecting wire (Kauffman Engineering, Cornelius, OR, 
USA) and silver epoxy. Finally, a thin layer of Nafion (LQ-1105, Ion Power, New Castle, 
DE, USA) is electrodeposited onto the fiber surface at 1 V for 30 s; the coated fiber is dried 
for 10 min at 70 °C.28 
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Data Collection and Analysis 
 Fast-scan cyclic voltammetry was performed on anesthetized mice using a Chem-
Clamp potentiostat (Dagan Corporation, Minneapolis, MN, USA), custom built hardware 
interfaced with PCIe 6341 & PCI 6221 DAC/ADC cards (National Instruments, Austin, 
TX), and a Pine Research headstage (Pine Research Instruments, Durham, NC, USA). 
WCCV 3.06 software (Knowmad Technologies LLC, Tucson, AZ, USA) was used to 
control the hardware and perform data analysis. The histamine waveform (-0.5 V to -0.7 V 
to +1.1 V to -0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 10 Hz for 10 min 
prior to data collection. Data were collected at 10 Hz. Histamine was evoked via biphasic 
stimulation applied through a linear constant current stimulus isolator (NL800A Neurolog, 
Digitimer North America LLC, Fort Lauderdale, FL, USA) with stimulations at 60 Hz, 360 
µA, 2 ms in width, and 2 s in length.  
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3 
kHz low pass filter). Four control evoked files, 10 min apart, were averaged for the control 
evoked histamine signal after which one compound from 3.2.1 was administered and files 
were collected at 0 min, 5 min, 10 min, and every 10 min thereafter until 120 min. For 
immepip-thioperamide experiments, data were collected for 60 min as described followed 
by administration of thioperamide immediately after the 60 min file was collected. Files 
were then collected for an additional 60 min in the same fashion as described above. 
Currents obtained were converted to concentrations through previously generated 
calibration factors for both histamine (2.825 µM nA-1) and serotonin (11 µM nA-1).24-25 At 
the completion of each experiment, a large voltage (~10 V; ~2 min) was applied to the 
CFM to lesion the surrounding tissue for histological analysis. Mice were euthanized, 
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brains were rapidly harvested and stored in 4% paraformaldehyde solution. Prior to 
sectioning, brains were transferred to 30% sucrose solution for 24 h minimum. Brains were 
rapidly frozen and sectioned into 25 µm slices (Thermo Scientific Cryotome FSE, Thermo 
Scientific, Waltham, MA, USA) and visualized under light microscope to confirm 
electrode placements. 
Statistical Analyses 
Average control response was generated from four current vs time traces per animal 
and averaged to create an overall group average. To determine the t 1/2, a code was custom 
written in Excel to fit the reuptake component of the curve and calculate the time taken to 
reach half the maximum amplitude. Exclusion criteria were based on outliers (via Grubbs 
test) and animals that did not survive the experimental paradigm. Standard error of the 
mean (SEM) was calculated using the average response of each animal (n = # animals). 
Significance between two points was determined by 2-tailed paired t-test and taken as p < 
0.05. For non-normally distributed data (via Shapiro Wilk test), the Kruskal-Wallis H test 
was used to determine significance and taken as p<0.05. All error bars represent the 
standard error of the mean (SEM). 
Animals and Surgical Procedure 
Animal procedures and protocols were in accordance with the regulations of the 
Institutional Animal Care and Use Committee (IACUC) at the University of South 
Carolina, accredited through the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). Male and female C57BL/6J mice aged 6-12 weeks 
were used. Animals were group housed with ad libitum access to food and water and were 
kept on a 12 h light/12 h dark cycle (lights on 0700/lights off 1900). 
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 Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed 
induction of deep and sustained anesthesia from an intraperitoneal injection of urethane 
(above). Mouse body temperature was maintained using a thermal heating pad (Braintree 
Scientific, Braintree, MA, USA). All surgical coordinates were taken in reference to 
bregma.29 A Nafion coated CFM was lowered into the posterior hypothalamus (AP: -2.45, 
ML: 0.50, DV: -5.45 to -5.55) and a stimulating electrode (insulated stainless-steel, 
diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial 
forebrain bundle (AP: -1.07, ML: +1.10, DV: -5.00).24 A pseudo-Ag/AgCl reference 
electrode, created by chloridizing a polished silver wire in HCl (15 s in 1 M HCl at 5 V), 
was placed in the contralateral hemisphere.  
 For the analysis of sex and estrous cycle differences control histamine and serotonin 
data were pooled. Due to the sensitivity of the measurements being made, we are unable to 
determine the estrous cycle stage prior to the experiment as we have observed in previous 
animals that doing so influences release and reuptake characteristics. For cycle 
determination, vaginal lavage was performed following the conclusion of data collection. 
Briefly, approximately 10 µL of sterile saline was administered and quickly removed from 
the vagina and then visualized under low power light microscope to determine estrous cycle 
stage via cytological examination.30 (Figure B1) 
3.3 Results 
3.3.1 Control Evoked Histamine and Serotonin Inhibition Does Not Vary Between Sexes 
 The stimulated histamine release and the resulting serotonin inhibition is shown in 
Figure 3.1. Panel A is a representative color plot of histamine FSCV with a CV inset in 
the top right corner. Averaged male stimulated histamine release (Ampmax: 7.54 ± 1.20 µM) 
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and serotonin inhibition (Ampmax: 42.53 ± 4.74 nM) is shown in blue in (B). In (C), the 
female stimulated histamine release (Ampmax: 7.11 ± 1.10 µM) and serotonin inhibition 
(Ampmax: 45.33 ± 4.72 nM) is shown in red. Tabulated in (D) are the max amplitude values 
for overall histamine peak release (Ampmax male-female: p = 0.80) and serotonin inhibition 
(Ampmax male-female: p = 0.98), the ratio of peak release to peak inhibition (HA/5HT: 
male: 0.19 ± 0.02; female: 0.16 ± 0.02; p = 0.34), and the rate of decay for the stimulated 
histamine release (t1/2 : male: 3.1 ± 0.4 s; female: 3.9 ± 0.7 s; p=0.34). The sample size was 
equal for male and female mice at n=20. 
 
Figure 3.1: Control evoked histamine is not significantly different between male 
and female mice. A) representative color plot shows the stimulated release and 
reuptake of histamine as the green event and the blue event is the inhibition of 
serotonin. Inset in the top right corner is the characteristic CV with peaks 
occurring around 0.2 V for histamine and 0.7 V for serotonin oxidation. The 
concentration vs time traces for the release of histamine and inhibition of 
serotonin is shown for B) male and C) female mice. The electrical stimulation (2 




3.3.2 Control Evoked Histamine and Serotonin Inhibition Does Not Vary Throughout 
the Estrous Cycle 
 We next evaluated the effect of estrous cycle stage on stimulated histamine release 
and inhibition of serotonin. Figure 3.2A shows the stimulated histamine release throughout 
estrus, metestrus, diestrus, and proestrus. We found no significant difference in the evoked 
histamine amplitude (Ampmax: estrus (blue; n=23): 6.58 ± 0.55 µM; metestrus (orange; 
n=16): 6.82 ± 0.74 µM; diestrus (yellow; n=10): 7.86 ± 1.33 µM; proestrus (green; n=10): 
5.80 ± 1.83 µM; p = 0.84 Kruskal-Wallis H-test) or t1/2 (estrus: 3.9 ± 0.7 s; metestrus: 5.4 
± 1.1 s; diestrus: 3.8 ± 0.9 s; proestrus: 4.3 ± 1.1 s; p = 0.79 Kruskal-Wallis H-test) of 
reuptake curve across estrous stages. The peak serotonin inhibition is shown across cycle 
stages in Figure 3.2B (Ampmax: estrus (blue; n=23): 44.70 ± 4.04 nM; metestrus (orange; 
n=16): 40.76 ± 5.93 nM; diestrus (yellow; n=10): 37.04 ± 4.92 nM; proestrus (green; 
n=10): 31.74 ± 5.17 nM; p = 0.27 Kruskal-Wallis H-test). These data are tabulated in Figure 
3.2C. 
 
Figure 3.2: Evoked histamine release does not significantly differ throughout 
estrous. (A) Evoked histamine release and (B) serotonin inhibition for female 
mice in estrous (blue, n=23), metestrus (orange, n=16), diestrus (yellow, n=10), 
and proestrus (green, n=10). The shaded grey bar represents the 2 s electrical 
stimulation. (C) Tabulated data covering the maximum amplitude of [histamine] 
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release, t1/2 of histamine clearance, maximum inhibition of [serotonin], and the 
ratio of [histamine]/[serotonin]. Data were analyzed via Kruskal-Wallis H-test. 
Significance was taken as p<0.05. 
 
 We observed the occurrence of two distinct release profiles in female mice that 
occurred exclusively while in estrus. Figure 3.3 shows the single (A), double (B), and 
combined (C) release profiles for evoked histamine. There was not a significant difference 
in the peak histamine amplitude (Ampmax: single (red; n=13): 6.70 ± 0.94 µM; double 
(purple; n=10): 6.42 ± 0.47 µM; p = 0.83 unpaired t-test) or in peak serotonin inhibition 
(Ampmax: single (red; n=13): 39.85 ± 5.65 nM; double (purple; n=10): 50.97 ± 5.38 µM; p 
= 0.88 unpaired t-test) between the single and double release events. At the end of data 
collection, a large voltage was passed through the electrode to lesion the tissue from which 
our measurements are made. This allows for histological verification of the electrode 
location placement. We hypothesized that the single and double release events were region 
specific. We found that electrode placements anterior to the target coordinates were more 
likely to result in a double peaked release. (Figure B2) 
 
Figure 3.3: Comparison of evoked histamine and serotonin signals during estrus. 
The different release profiles obtained for [histamine] vs time in female mice during 
estrus are shown in (A) single release (red), (B) double release (purple), and (C) the 
combined average of the single and double profiles. Maximum amplitude of 
histamine release ([HA]Ampmax: single (red; n=13): 6.70 ± 0.94 µM; double (purple; 
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n=10): 6.42 ± 0.47 µM; p = 0.83 unpaired t-test) and serotonin inhibition 
([5HT]Ampmax: single (red; n=13): 39.85 ± 5.65 nM; double (purple; n=10): 50.97 ± 
5.38 µM; p = 0.88 unpaired t-test) were not significantly different. Significant was 
taken as p<0.05. 
 
3.3.3 H1R and H2R Pharmacology 
 First, we investigated how the antagonism of post-synaptic receptors H1 and H2 
would affect the release and reuptake of hypothalamic histamine. Figure 3.4 shows the 
male and female response to diphenhydramine (DPH) (20 mg kg-1), an H1 antagonist, and 
zolantidine (10 mg kg-1), an H2 antagonist. In column (A) the administered compound and 
sex is given, (B) a representative color plot of histamine release and serotonin inhibition, 
(C) cyclic voltammograms confirming the electrochemical identities of histamine and 
serotonin, (D) concentration vs time plots of control evoked histamine release (blue) and 
following drug administration (green). No significant change in evoked histamine release 
was seen in male mice given DPH (Di) (n=5; Ampmax: control: 9.22 ± 3.06 µM; post-drug: 
9.38 ± 2.66 µM; p = 0.83 paired t-test) or zolantidine (Diii) (n=5; Ampmax: control: 5.84 ± 
0.55 µM; post-drug: 4.90 ± 0.60 µM; p = 0.33 paired t-test). Significant slowing of 
histamine reuptake was obtained 50 min following administration of DPH (Di) (t1/2 : 
control: 2.7 ± 0.4 s; post-drug: 7.2 ± 1.1 s; p = 0.014 paired t-test) but not following 
zolantidine (Diii) (t1/2 : control: 4.2 ± 1.3 s; post-drug: 3.2 ± 1.0 s; p = 0.46 paired t-test). 
In (Dii), female mice respond to DPH with a slight decrease in histamine amplitude (n=4; 
Ampmax: control: 6.78 ± 0.16 µM; post-drug: 5.34 ± 0.56 µM; p = 0.077 paired t-test) and 
a slowing of reuptake (t1/2 : control: 3.3 ± 0.8 s; post-drug: 12.0 ± 2.6 s; p = 0.042 paired t-
test). Female response to zolantidine was similar to male with no change in histamine 
amplitude (n=5; Ampmax: control: 5.40 ± 0.65 µM; post-drug: 5.45 ± 0.87 µM; p = 0.96 
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paired t-test) or clearance profile (t1/2 : control: 2.7 ± 0.7 s; post-drug: 3.8 ± 1.6 s; p = 0.59 
paired t-test).  
 
Figure 3.4: Post-synaptic H1 and H2 receptor targeting highlights differential 
receptor-release communication mechanisms. (A) the drug and mouse’s sex are 
listed. (B) a representative color plot for each grouping of animals is shown. The 
green bar represents the 2 s electrical stimulation. (C) a representative cyclic 
voltammogram from each cohort of animals. The CV is obtained from the vertical 
dashed line in each color plot in B. The blue shading covers the oxidation peak of 
histamine and the red shading highlights the oxidation serotonin. (D) concentration 
versus time traces for control (blue) and post-drug (green) evoked histamine. Traces 
are obtained from the horizontal dashed lines in color plot in Bi-iv. 
 
3.3.4 Distinctive H3R Autocontrol Between Males and Females 
 We established there was no difference between histamine release, serotonin 
inhibition, or the ratio of HA/5HT between male and female mice in 3.3.1. We wanted to 
further investigate the regulatory role of H3 receptors in male and female mice by 
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administering an H3R agonist, immepip (5 mg kg-1), and an H3R antagonist, thioperamide 
(20 mg kg-1). 
In Figure 3.5, male (Di) and female (Dii) mice respond similarly to H3R agonism 
with an overall decrease in max amplitude (male, n=5: Ampmax: control: 7.72 ± 1.55 µM; 
post-drug: 4.77 ± 1.56 µM; p = 0.024; female, n=5: Ampmax: control: 6.20 ± 0.86 µM; post-
drug: 3.58 ± 0.51 µM; p = 0.005) and no change in histamine clearance (male: t1/2 : control: 
4.5 ± 1.7 s; post-drug: 2.9 ± 0.6 s; p = 0.4; female: t1/2 : control: 5.6 ± 1.8 s; post-drug: 5.6 
± 2.6 s; p = 1 paired t-test). 
 
Figure 3.5: H3 targeting drugs highlight distinct response of male and female mice. 
(A) the drug and mouse’s sex are listed. (B) a representative color plot for each 
grouping of animals is shown. The green bar represents the 2 s electrical 
stimulation. (C) a representative cyclic voltammogram from each cohort of 
animals. The CV is obtained from the vertical dashed line in each color plot in B. 
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The blue shading covers the oxidation peak of histamine and the red shading 
highlights the oxidation serotonin. (D) concentration versus time traces for control 
(blue) and post-drug (green) evoked histamine. Traces are obtained from the 
horizontal dashed lines in color plot in Bi-iv. 
 
Thioperamide administration resulted in a significant increase in evoked 
hypothalamic histamine in male mice (Diii) (n=5; Ampmax: control: 8.83 ± 1.35 µM; post-
drug: 12.10 ± 1.75 µM; p=0.046) while trending toward a significant slowing of reuptake 
(t1/2 : control: 4.5 ± 1.7 s; post-drug: 9.9 ± 2.2 s; p = 0.051). However, in the female mice, 
no such change in amplitude was observed. Female mice (Div) exhibit no change in 
histamine amplitude (n=5; Ampmax: control: 7.37 ± 1.40 µM; post-drug: 7.01 ± 1.65 µM; 
p=0.39) or rate of reuptake (t1/2 : control: 4.2 ± 1.6 s; post-drug: 3.9 ± 1.3 s; p = 0.48) 
following the same dose of thioperamide. 
 
Figure 3.6: Thioperamide raises histamine to control levels 
following immepip pretreatment. (A) FSCV [HA] vs time profiles 
of evoked histamine for control (n=5, blue), 60 min following 
immepip (n=5, orange), and 40 min following thioperamide after 
60 min immepip (n=4, green). Error bars have been eliminated for 
clarity. (B) max amplitude of evoked histamine for control (blue), 
60 min immepip (orange), and 40 min following thioperamide 
after initial 60 min immepip (green). Significance between two 




Given that females did not respond to 20 mg kg-1 thioperamide but did respond to 
the H3 agonist, immepip, we hypothesized there was a threshold level of extracellular 
histamine that female mice were unable to surpass. Therefore, we administered immepip 
(5 mg kg-1) for 60 min to decrease evoked histamine and then administered thioperamide 
(20 mg kg-1) to determine if histamine levels would increase to control or exceed control 
levels. Figure 3.6A shows the [HA] vs time profiles of control (blue), 60 min post-immepip 
(orange), and 40 min post-thioperamide (green). Error bars have been omitted for clarity. 
Following a significant decrease from immepip (vida supre), we show that thioperamide 
elevates stimulated histamine only to around control level (Ampmax: immepip: 3.58 ± 0.51 
µM; post-immepip-thioperamide: 5.89 ± 1.13 µM; p=0.13); we were unable to increase 
evoked histamine in female mice to above control (Ampmax: control: 6.20 ± 0.86 µM; post-
immepip-thioperamide: 5.89 ± 1.13 µM; p=0.83 paired t-test). 
3.3.5 Histamine is Packaged via the Vesicular Monoamine Transporter 
 We investigated the packaging mechanisms of histamine in the brain using two 
vesicular monoamine transporter (VMAT) inhibitors with different affinities for VMAT1 
and VMAT2 (tetrabenazine (TBZ): 10 mg kg-1; reserpine: 10 mg kg-1). Each compound 
functions by inhibiting packaging of histamine (and other neurochemicals) into vesicles 
prior to exocytosis which results in the intracellular neurochemicals being enzymatically 
metabolized in the cytosol. Both reserpine and tetrabenazine required modification to the 
saline vehicle to fully dissolve the compounds. Reserpine was dissolved in 0.1 % AcOH in 
saline and tetrabenazine required 10% DMSO in saline with 1 M HCl (10 µL mL-1). 
Vehicle solutions were administered (5 mL kg-1) to each mouse for 30 min between control 
files and drug files to determine any vehicle effects on the evoked histamine and serotonin 
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profiles. Vehicle injections did not significantly change the evoked release in males or 
females; however, female mice did have a more obvious change in release amplitude 
following vehicle.  
 Reserpine vehicle (0.1% AcOH in saline) injection did not significantly change 
histamine amplitude from control (male, n=5: Ampmax: control: 5.41 ± 1.01 µM; AcOH 
vehicle: 5.43 ± 0.64 µM; p=0.98) (female, n=5: Ampmax: control: 9.17 ± 1.22 µM; AcOH 
vehicle: 7.76 ± 1.01 µM; p=0.053). However, 60 min following reserpine injection, a 
significant decrease in evoked histamine amplitude was observed in both male (Figure 3.7 
Di) (Ampmax: AcOH vehicle: 5.43 ± 0.64 µM; reserpine: 2.72 ± 0.47 µM; p=0.009) and 
female (Figure 3.7 Dii) mice (Ampmax: AcOH vehicle: 9.17 ± 1.22 µM; reserpine: 6.53 ± 
1.01 µM; p=0.016). There was no change in the rate of reuptake of histamine for either sex 
(male: t1/2 : control: 2.4 ± 0.7 s; reserpine: 2.8 ± 0.7 s; p=0.51) (female: t1/2 : control: 6.3 ± 
2.5 s; reserpine: 4.4 ± 1.6 s; p=0.23).  
Tetrabenazine vehicle (acidified 10% DMSO) administration did not significantly 
change control evoked histamine (male, n=5: Ampmax: control: 7.51 ± 1.32 µM; DMSO: 
7.08 ± 1.42 µM; p=0.18) (female, n=5: Ampmax: control: 9.02 ± 1.45 µM; DMSO: 7.56 ± 
0.75 µM; p=0.27). After the mice received TBZ, a significant decrease in evoked histamine 
was observed for both sexes (male: Ampmax: DMSO: 7.08 ± 1.42 µM; TBZ: 5.49 ± 1.44 
µM; p=0.023) (female: Ampmax: DMSO: 7.56 ± 075 µM; TBZ: 3.83 ± 0.40 µM; p=0.008) 
3.3.6 Pharmacological Manipulation of Histamine Synthesis and Metabolism 
 Finally, we targeted the beginning and end of histamine’s metabolic life cycle in 
the central nervous system. We used tacrine, an N-methyltransferase inhibitor, and α-




Figure 3.7: VMAT inhibition lowers evoked histamine release. (A) the drug and 
mouse’s sex are listed. (B) a representative color plot for each grouping of animals 
is shown. The green bar represents the 2 s electrical stimulation. (C) a 
representative cyclic voltammogram from each cohort of animals. The CV is 
obtained from the vertical dashed line in each color plot in B. The blue shading 
covers the oxidation peak of histamine and the red shading highlights the oxidation 
serotonin. D) concentration versus time traces for control (blue) and post-drug 
(green) evoked histamine. Traces are obtained from the horizontal dashed line 
‘histamine’ in color plots in Bi-iv. 
 
Administration of tacrine to male mice (Figure 3.8 Di) resulted in no change in histamine 
amplitude (n=5, Ampmax: control: 9.56 ± 0.89 µM; tacrine: 9.41 ± 1.22 µM; p=0.92) and a 
slowed clearance of histamine from the extracellular space (t1/2 : control: 2.8 ± 0.8 s; 
tacrine: 6.0 ± 0.7 s; p=0.025). Female mice (Figure 3.8 Dii) displayed no amplitude change 
following tacrine (n=4, Ampmax: control: 7.01 ± 1.79 µM; tacrine: 7.74 ± 1.85 µM; p=0.22) 
and had a slowing of reuptake that trended towards a significant change (t1/2 : control: 4.8 
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± 1.4 s; tacrine: 4.9 ± 2.4 s; p=0.095). It’s clear that in both male and female mice, inhibiting 
the intracellular metabolic enzyme results in no change in overall release of histamine but 
does cause histamine to remain in the synapse for a prolonged amount of time due to the 
concentration gradient created intracellularly. 
 
Figure 3.8: Inhibition of histidine decarboxylase lowers evoked histamine release 
while inhibiting histamine N-methyltransferase results in histamine remaining in 
the extracellular space. (A) the drug and mouse’s sex are listed. (B) a representative 
color plot for each grouping of animals is shown. The green bar represents the 2 s 
electrical stimulation. (C) a representative cyclic voltammogram from each cohort 
of animals. The CV is obtained from the vertical dashed line in each color plot in 
B. The blue shading covers the oxidation peak of histamine and the red shading 
highlights the oxidation serotonin. (D) concentration versus time traces for control 
(blue) and post-drug (green) evoked histamine. Traces are obtained from the 
horizontal dashed line ‘histamine’ in color plots in Bi-iv. 
 
 Due to the limited amount of FMH we had available, we combined the male and 
female responses into one grouping. We have shown that 60 min following inhibition of 
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histamine synthesis via FMH, a significant decrease in stimulated histamine was observed 
(Figure 3.8 Diii/iv) (n=2 male, 2 female; Ampmax: control: 8.59 ± 1.86 µM; post-FMH: 
5.83 ± 1.24 µM; p=0.038). There was no change in histamine clearance ((t1/2: control: 2.4 
± 0.2 s; FMH: 2.3 ± 0.4 s; p=0.82) 
3.4 Discussion 
3.4.1 Histamine FSCV in male and female mice 
The exclusion of females from pharmacological testing can have serious 
consequences for the health and safety of patients.31 Estrogen has been shown to be an 
important regulator in the ventromedial nucleus (VMN) of the hypothalamus.23, 32-33 H1R 
and estrogen receptor alpha (ERα) mRNA are co-expressed in histaminergic neurons23, 34 
and ERβ are expressed in the TMN.35 The localization of estrogen receptors on histamine 
projections highlights the potential role estrogen plays in regulating immune response. 
Indeed, estrogen and progesterone have been shown to mitigate the acute inflammatory 
response to lipopolysaccharide exposure.36-39 Additionally, inflammatory diseases and the 
susceptibility to the occurrence of diseases are more likely in post-menopausal women than 
pre-menopausal women and age matched males.40-41 
In this study we set out to investigate the machinery of the central histaminergic 
systems of male and female mice via response to various pharmaceutical challenges. Under 
control conditions, we did not find any differences in the release of hypothalamic histamine 
in male and female mice (Figure 3.1). This finding is in agreement with our previous work 
that compared hippocampal serotonin between sexes and found no statistical differences.42 
Our results differed from some literature reports that suggested histamine turnover and 
histamine cerebrospinal fluid concentration are higher in females43 or show lowered 
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histamine in females.22 FSCV is accompanied by a large aphysiological stimulation which 
releases a substantial amount of neurochemicals and is a fundamentally different type of 
measurement than other sampling techniques. In vivo measurements keep brain circuits 
intact and are often different than data obtained from ex vivo brain slices.44 Our data are 
unnormalized and highlight the high level of conservation in neurochemical regulatory 
mechanisms across individual mice. 
There is an intrinsic belief that there may be neurochemical differences between 
the different stages of the estrous cycle that has limited the use of females in research.45 
Due to histamine’s potential role in neuroinflammation, this belief may be even stronger; 
the extent of immune reactivity has been thought to depend on the different stages of the 
estrous cycle.46-47 Therefore, we compared evoked histamine in female mice during 
different stages of the estrous cycle and found that histamine was not significantly different 
throughout (Figure 3.2). This finding is not surprising given our prior experience with 
measuring neurotransmitters with FSCV where we have had to employ aggressive means 
to affect a significant but small change from homeostasis24, 42, such as high doses of SSRIs 
which correspond to profound behavioral alterations.48 Interestingly, we observed a double 
release event that occurred during the estrus stage of the female cycle. We have previously 
observed a similar phenomenon in the prefrontal cortex (pFC) regarding stimulated 
serotonin release.49 West et al determined that the occurrence of a single release or double 
release was dependent upon the specific region of the pFC the CFM was located. We 
applied that assumption to the posterior hypothalamus as well and found that double peaks 
were most likely to occur when the CFM was located anterior to our target coordinates. 
The ventromedial nucleus, periventricular nucleus, and dorsomedial nucleus are located in 
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this area and known to have a very high level of hormonal regulation.50-52 Neuronal mRNA 
sampled from VMN neurons showed colocalized expression of ERα and H1, H2, and H3 
receptors.23 Indeed the regulation of lordosis has been shown to be dependent on the 
interplay of histaminergic neurons and estrogens through histamine and estrogen 
receptors.23, 34, 53 
We conduct our histamine measurements in a specifically targeted region of the 
posterior hypothalamus where we are able to detect both evoked histamine and the resulting 
inhibition of serotonin. This has been shown to be an H3R mediated process by our lab and 
others.1, 24, 26-27 After confirming no statistical differences in evoked histamine between 
male and female mice and throughout the estrous cycle, we analyzed the level of serotonin 
inhibition resulting from histamine release in the same mice. Unsurprisingly, the overall 
amount of serotonin inhibition is not different between males and females, and the ratio of 
maximum release to peak inhibition does not differ (Figure 3.2). Throughout the estrous 
cycle serotonin did not vary significantly but a relative trend can be seen between histamine 
and serotonin amplitudes across cycle stages. As histamine exhibited two release profiles, 
we also compared the corresponding serotonin data of single and double events. A double 
peaked histamine release resulted in a larger amount of inhibition, but the difference was 
not significant (Figure 3.3). These results highlight the highly conserved nature of both 
the histamine and serotonin systems to maintain a homeostatic balance in the brain. 
3.4.2 Histamine receptor pharmacology in male and female mice 
After determining the evoked release of histamine was conserved between male 
and female mice, we wanted to explore how different receptor targeting compounds 
affected the release and reuptake of histamine. Antihistamines are compounds most 
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commonly prescribed for common allergies and target post-synaptic H1 or H2 receptors. 
First generation antihistamines, like diphenhydramine, readily cross the blood brain barrier 
and block the H1 receptor. Histamine is unable to activate the receptor to propagate 
signaling resulting in the common side effect of drowsiness. In both male and female mice, 
when H1 activation is inhibited, a slowing of histamine clearance is observed, presumably 
to allow histamine to remain in the synapse and activate the receptor after which it would 
then be reuptaken. Interestingly, these results point to a communication between H1 and 
membrane transport proteins.54 The results of zolantidine administration were unexpected 
given how H1 antagonism effected reuptake. Even as a brain penetrating potent H2 
antagonist, zolantidine did not cause any significant changes in the release and reuptake 
profile of histamine in male or female mice (Figure 3.4). This could be due to the 
difference between diphenhydramine being an inverse agonist and zolantidine being an 
antagonist.55 H2 receptors are widely expressed throughout the hypothalamus just as H1 
receptors but reuptake signaling mechanisms appear not to be linked to H2 activation and 
propagation. 
There is a substantial amount of literature documenting the neuromodulatory role 
and autoregulatory role of the H3 receptor.1, 5, 26-27 We previously used the H3R antagonist 
thioperamide when developing histamine FSCV24-25 and anticipated seeing robust changes 
in brain histamine when targeting H3R. However, when an equivalent dose of thioperamide 
was administered to female mice, a robust increase in histamine release did not occur. This 
contrasts with previous work that observed behavior following thioperamide treatment and 
found similar effects in and male female rats.56 After confirming there was consistently no 
change in female mice, we hypothesized that H3R expression in females possibly is lower 
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and administering a higher dose (50 mg kg-1) would test this notion. The higher dose did 
not result in a similar elevated release as in male mice and we ruled out receptor expression. 
We then tested whether immepip, an H3R agonist, would have a differential response in 
male and female mice. We found that H3R agonism resulted in an overall decrease in 
evoked histamine in both male and female mice without affecting the clearance slope 
(Figure 3.4). We hypothesized potential evolutionary regulatory mechanisms are present 
in female mice that do not allow histamine to elevate above a certain threshold. Ferretti et 
al. suggested that stressor-induced increases in histamine release may be lower in females 
than it is in males.22 Therefore, we tested this hypothesis by pretreating female mice with 
immepip to cause a significant decrease in evoked histamine. Following immepip, 
administration of thioperamide (20 mg kg-1) should now increase histamine to control or 
above control levels. In Figure 3.5, following a significant decrease in evoked histamine, 
thioperamide was only able to increase histamine back to near control levels, supporting 
our hypothesis that there are intrinsic mechanisms present in the female immune system 
that strictly regulate the levels of histamine in the brain. This increased control may have 
evolutionary underpinnings as it is often thought that female animals exhibit more 
homeostatic control and that female hormones, estrogens and progesterones, have 
neuroprotective functions.57-58 
Studies have shown that females experience an increased risk of developing 
inflammatory disorders later in life, particularly post-menopause.40-41 Therefore we wanted 
to test whether age or circulating hormone levels could influence the female response to 
thioperamide. There are three potential strategies we identified. 1) perform voltammetry 
experiments on mice that are undergoing or have undergone menopause (age 9-12+ 
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months).59 2) chemically or physically eliminate ovaries through ovotoxin administration 
or ovariectomy. 3) eliminate the influence of estrogens on the immune response through 
pretreatment with an aromatase inhibitor, letrozole. By pretreating female mice with 
letrozole and then administering thioperamide, we would be able to view how the female 
histaminergic system responds to H3R antagonism in the absence of estrogenic regulation. 
This is the focus of future experiments. 
3.4.3 Vesicular packaging of histamine in male and female mice 
Vesicular packaging is a crucial step for monoamine neurotransmission and 
disruptions can have downstream effects. Brain histamine can originate from neurons, glia, 
and mast cell degranulation.5 We targeted VMAT2 with two compounds, tetrabenazine and 
reserpine and examined their effect on histamine release. Tetrabenazine is selective for 
VMAT2, while reserpine has affinity for both VMAT1 and VMAT2. However, VMAT2 
is responsible for packaging in neurons, while VMAT1 is exclusively located in endocrine 
cells.60 Additionally, Erickson et al. demonstrated that histamine displayed a 30-fold higher 
affinity for VMAT2 over VMAT1 and reserpine had about 3x affinity for VMAT2 over 
VMAT1.61 Both reserpine and tetrabenazine caused significant decreases in overall evoked 
histamine in males and females, with females responding the strongest to tetrabenazine 
(Figure 3.6 Div). This could also be due to the initially high control signals obtained in 
that cohort of mice which makes the decrease appear more robust. We also confirmed that 
the majority of evoked histamine was neuronal or glia based and most likely not related to 
mast cell degranulation. This confirmed that histamine has similar prerelease mechanisms 
to other common neurotransmitters such as dopamine and serotonin and will better help 
understand the altered mechanisms during inflammatory states. 
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3.4.4 Influence of Enzyme Inhibition on Evoked Histamine 
We tested how inhibiting histamine synthesis might affect evocable histamine. 
Other groups have used FMH to successfully lower histamine and our data are in good 
agreement with those reports.62-64 Although the goal of this work was to highlight the male 
and female response to compounds separately, we combined the sexes’ responses in the 
case of FMH (20 mg kg-1) due to the limited amount of the compound available. Despite 
the inhibition of synthesis, there still is evocable histamine 60 min after ip injection, most 
likely due to the large aphysiological nature of our electrical stimulation. CNS histamine 
is metabolized exclusively by HA N-methyltransferase which is located intracellularly. By 
blocking the enzyme, a concentration gradient is created between the intra- and 
extracellular space and histamine spends a prolonged time in the synapse. The male and 
female mice responded similarly both having significant slowing of reuptake following 
tacrine (ip; 2 mg kg-1) (Figure 3.7 Diii, iv). Tacrine has additional affinity for blocking 
acetylcholine esterase which has been explored for cognitive boosting abilities in 
Alzheimer’s patients.65-66 Our data show that the metabolic pathway of histamine, 
including synthesizing and degrading enzymes, is highly conserved between male and 
female mice. 
What we are currently working towards is using this collection of novel 
simultaneous histamine and serotonin data to create a mathematical model of the synapse. 
We have made progress on the serotonin system49, 67 and have investigated parts of the 
histamine system24, 68 but have not fully elucidated the mechanisms regulating the synapse 
outside of standard H3R mediated inhibition.24 A model built using these data will capture 
how changes in histamine receptor functionality, vesicular packaging, and synthesis and 
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metabolism can affect the transmission of histamine and serotonin, a critical step in 
understanding the differences between healthy and inflamed immune systems. 
3.5 Conclusion 
 In this study, we investigated the pharmacological response of the male and female 
histamine system in the brain. We compared control evoked histamine between male and 
female mice and found no differences between them as well as no influence from the 
estrous cycle on histamine release. We targeted histamine receptors H1, H2, H3, and H4, 
vesicular packaging, synthesis, and metabolism. We found that the histaminergic system is 
highly conserved between the sexes but females appear to have a stronger regulatory 
control over increased histamine levels mediated through H3R. Our data highlight the 
importance of considering biological sex as a variable when evaluating pharmacology data 
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Histamine is an important mediator of inflammation and immune response in the 
peripheral nervous system. Much less is known about histamine’s functions within the 
brain and central nervous system. Only one metabolic pathway is available for histamine 
within the brain through the intracellularly located histamine N-methyltransferase, despite 
there not being a dedicated transport protein for histamine identified. Stimulated histamine 
exhibits similar release and reuptake kinetics to that of common monoamine systems, thus, 
we investigated which transporters are responsible for the reuptake of histamine in the 
brain. We screened six agents to inhibit the serotonin transporter (SERT), norepinephrine 
transporter (NET), dopamine transporter (DAT), and organic cation transporter (OCT) and 
found compounds showing appreciable slowing of histamine clearance all have 
antidepressant activity. We focused on the role of SERT inhibition towards histamine 
clearance by utilizing a transgenic mouse model, the SERT Met172, which is insensitive 
to certain selective serotonin reuptake inhibitors (SSRI). The SSRI escitalopram 
significantly slowed histamine clearance in Met172 mice absent SERT antagonism. Our 
data rule out SERT’s contribution toward histamine reuptake and are in agreement with 
previous reports that propose OCT as the main transporter responsible for clearance. Our 
study highlighted key off-target mechanisms of antidepressants and the need to better 
understand the full spectrum of the mechanisms of these agents to improve their clinical 
efficacy. 
4.1 Introduction 
 Histamine is an important monoamine in the central nervous system (CNS) and 
dysregulation can lead to behavioral abnormalities.1-4 Therapies targeting the histaminergic 
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system are much less robust than other more common monoamine strategies and have 
failed to reach clinical relevance for neurological disorders.3, 5-6 There is a wide gap 
between understanding histamine’s roles in the CNS and developing successful therapies 
because histamine’s role and its interaction with other neurotransmitter systems remain 
understudied. Histamine controls monoamine release through H3 receptors on presynaptic 
terminals but understanding this regulation in the context of CNS disorders is unclear.7-12 
 In the CNS, histamine is exclusively metabolized to tele-methylhistamine through 
histamine N-methyltransferase.13 This metabolic route is only available for central 
histamine; peripheral histamine undergoes its own specific degradation pathway.14 There 
is evidence for partial histamine uptake into astrocytes15 and synaptosomes16, but a 
dedicated histamine transporter has not yet been identified. Previous work from the 
Hashemi lab reported that the reuptake curve of histamine, as measured by FSCV, was best 
fit with first order Michaelis-Menten kinetics17 similar to dopamine and serotonin that have 
dedicated membrane transporters.18-19 Therefore, we sought to establish which mechanisms 
might be responsible for this (suggestively) active reuptake of histamine in vivo. 
 Previous work from Lyn Daws’ lab has shown that the monoamine transporters 
(dopamine transporter (DAT), norepinephrine transporter (NET), serotonin transporter 
(SERT)) are not particularly selective for their dedicated substrate and regularly will 
reuptake one another’s substrates; a phenomenon she coined ‘promiscuous reuptake.’20 
Additionally, there is evidence that the non-specific membrane bound organic cation 
transporter (OCT2/3) and plasma membrane bound transporter (PMAT) play a significant 
role in histamine reuptake.21-22 
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In this work, we inhibited SERTs (with three separate agents), DATs, NETs, and 
OCTs and found that all agents, with the exception of the DAT inhibitor, slowed the 
reuptake of histamine. In agreement with previous findings, OCT inhibition resulted in the 
strongest inhibition of histamine reuptake.21-23 However, due to promiscuous reuptake, our 
results do not definitively identify which transporter is responsible for histamine uptake. 
To hone in better on the reuptake mechanism involved, we utilized a transgenic mouse 
model, the SERT Met172, generated by Randy Blakely at Florida Atlantic University. In 
Met172 mice, the SERT protein coding has a single amino acid substitution (isoleucine172 
 methionine172) that renders these mice insensitive to several SSRIs including 
escitalopram, which was included in the initial reuptake screening.24 Importantly, this 
substitution does not affect the function of the SERT.25 We found that administration of 
escitalopram to both Met172 and wild-type (WT) mice results in the inhibition of histamine 
reuptake, despite escitalopram not inhibiting the SERT, suggesting that SERTs do not play 
a major role in histamine reuptake. These results suggest that there exists an active reuptake 
mechanism for histamine, primarily through OCTs and negligible uptake through SERTs. 
This information is critical for improving the efficacy of CNS targeting pharmaceuticals. 
4.2 Materials and Methods 
Chemicals and Reagents 
 Escitalopram oxalate (Sigma Aldrich, St. Louis, MO, USA) at 10 mg kg-1 , GBR 
12909 (Sigma Aldrich) at 15 mg kg-1, desipramine hydrochloride (Sigma Aldrich) at 15 
mg kg-1, citalopram hydrobromide (Sigma Aldrich) at 5 mg kg-1, sertraline hydrochloride 
(Sigma Aldrich) at 10 mg kg-1, and decynium-22 (Sigma Aldrich) at 0.1 mg kg-1 were 
individually dissolved in sterile saline (0.9% NaCl solution, Hospira, Lake Forest, IL, 
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USA) and administered via intraperitoneal (ip) injection at a volume of 5 mL kg-1 body 
weight. Urethane (Sigma Aldrich, St. Louis, MO, USA) was dissolved in sterile saline at 
25% w/v and administered ip at 7 µL/g mouse body weight for surgical anesthesia. 
Electrode Fabrication 
 All electrodes are made in house. A single carbon fiber is aspirated into a 
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim 
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige, 
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is then 
trimmed under light microscope to ~150 µm by scalpel. An electrical connection is forged 
with the fiber through a stainless-steel connecting wire and silver epoxy. Finally, a thin 
layer of Nafion (LQ-1105, Ion Power, New Castle, DE, USA) is electrodeposited onto the 
fiber surface at 1 V for 30 s; the coated fiber is dried for 10 min at 70 °C.26 
Data Collection and Analysis 
 Fast-scan cyclic voltammetry was performed on anesthetized mice using a Dagan 
potentiostat (Dagan Corp., Minneapolis, MN, USA) and custom built hardware interfaced 
with PCIe 6341 & PCI 6221 DAC/ADC cards (National Instruments, Austin, TX) and a 
Pine Research headstage (Pine Research Instruments, Durham, NC, USA). WCCV 3.06 
software (Knowmad Technologies LLC, Tucson, AZ, USA) was used to control the 
hardware and perform data analysis. The histamine waveform (-0.5 V to -0.7 V to +1.1 V 
to -0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 10 Hz for min prior to data 
collection. Data were collected at 10 Hz. Histamine was evoked via biphasic stimulation 
applied through a linear constant current stimulus isolator (NL800A Neurolog, Digitimer 
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North America LLC, Fort Lauderdale, FL, USA) with stimulations at 60 Hz, 360 µA, 2 ms 
in width, and 2 s in length.  
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3 
kHz low pass filter). Four control evoked files, 10 min apart, were averaged for the control 
evoked histamine signal after which drug was administered and files were collected at 0 
min, 5 min, 10 min, and every 10 min thereafter until 120 min. Currents obtained were 
converted to concentrations through previously generated calibration factors for both 
histamine (2.825 µM nA-1) and serotonin (11 µM nA-1).17, 27 Mathematical modeling was 
via a previous model for histamine cells in MatLab.28 
Statistical Analyses 
 Average control response was generated from four current vs time traces per animal 
and averaged to create an overall group average. Exclusion criteria were based on outliers 
(via Grubbs test) and animals that did not survive the experimental paradigm. Standard 
error of the mean (SEM) was calculated using the average response of each animal (n = # 
animals). Significance between two points was determined by student’s t-test and taken as 
p < 0.05. All error bars represent the standard error of the mean (SEM). 
Animals and Surgical Procedure 
 Animal procedures and protocols were in accordance with the regulations of the 
Institutional Animal Care and Use Committee (IACUC) at the University of South 
Carolina, accredited through the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). Male and female SERT Met 172 knock in mice on 
a 129S6/S4 background were backcrossed with C57BL/6J mice and wild type mice (WT; 
C57 mice with 129 wildtype SERT gene (Ile172)) aged 6-20 weeks were used. Animals 
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were group housed with ad libitum access to food and water and were kept on a 12 h 
light/12 h dark cycle (lights on 0700/lights off 1900). 
 Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed 
induction of deep and sustained anesthesia from an intraperitoneal injection of urethane. 
Mouse body temperature was maintained using a thermal heating pad (Braintree Scientific, 
Braintree, MA, USA). All surgical coordinates were taken in reference to bregma.29 A 
Nafion coated CFM was lowered into the posterior hypothalamus (AP: -2.45, ML: 0.50, 
DV: -5.45 to -5.55) and a stimulating electrode (insulated stainless-steel, diameter: 0.2 mm, 
untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial forebrain bundle 
(AP: -1.07, ML: +1.10, DV: -5.00).27 A pseudo-Ag/AgCl reference electrode, created by 
chloridizing a polished silver wire in HCl (15 s in 1 M HCl at 5 V), was placed in the 
contralateral hemisphere.  
4.3 Results 
 To screen potential monoamine transporters responsible for histamine reuptake, we 
tested the effects of monoamine transport inhibitors on histamine reuptake. In Figure 4.1, 
we measured evoked histamine (control, blue) and then pharmacologically inhibited the 
following transporter proteins (post-drug, green): dopamine transporters (DATs), serotonin 
transporters (SERTs), and norepinephrine transporters (NETs) with the following agents 
(ip; n = 5 each): GBR 12909 (DAT inhibitor, 15 mg kg-1), escitalopram (SERT inhibitor, 
10 mg kg-1), citalopram (SERT inhibitor, 5 mg kg-1), sertraline (SERT inhibitor, 10 mg kg-
1), and desipramine (NET inhibitor, 15 mg kg-1). We found that in all cases except for DAT 
inhibition, there was slowing of the rate of histamine reuptake that peaked at 60 min. The 
ability of both SERT and NET inhibitors to slow histamine clearance suggests a less 
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selective transporter might be involved. We therefore turned towards organic cation 
transporters (OCTs) and plasma membrane monoamine transporters (PMATs) which were 
inhibited with decynium-22 (OCT and PMAT inhibitor, 0.1 mg kg-1), providing evidence 
that this agent also slowed histamine clearance. 
 
Figure 4.1: Histamine reuptake is inhibited by monoamine transporter inhibitors. 
(A) Control hypothalamic histamine (blue) and 60 min post (i) GBR 12909 (ip, 
15 mg kg-1), (ii) escitalopram (10 mg kg-1), (iii) sertraline (10 mg kg-1), (iv) 
desipramine (15 mg kg-1), (v) citalopram (5 mg kg-1), and (vi) decynium-22 (0.1 
mg kg-1) (green; n=5, each) Stimulation marked by grey box at 5-7 s. Error (± 
standard error of the mean) is a shaded region around traces. Doses were reported 
in prior work to create behavioral shifts or neurochemical changes.26, 30-34 
 
Instead of only examining t1/2 here, we took a more sophisticated kinetic approach. 
We used a previously developed mathematical model for histamine dynamics28 to 
investigate how physiological parameters could be adjusted to best capture curves for 
escitalopram, citalopram, sertraline, and decynium-22. Model curves (dashed lines) are 
compared to experimental curves (solid lines) in Figure 4.2. In all four cases, we found 
that the major parameter change was a 50% reduction in the transport of extracellular 
histamine back into the cell, consistent with the inhibition of histamine reuptake. To further 
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narrow down which transporters are the largest contributor to histamine reuptake we used 
the SERT Met172 mouse. 
 
Figure 4.2: Modeled transporter data. Each panel shows the 
experimental curves (solid lines) and model predictions (dashed 
lines) both pre- and post-drug for the three different SSRIs and 
decynium-22. The main difference between the pre-drug and 
post-drug model curves was a 50% decrease in the reuptake of 
histamine from the extracellular space into the histamine 
varicosity. In the cases of escitalopram and decynium-22, the 
uptake into glial cells was partially blocked, which is consistent 
with the fact that the post-drug experimental curves are higher 
and flatter in those two cases. 
 
This mouse bears a single amino acid substitution (Ile172 is encoded in humans 
and mice and here are converted to Met172) that impairs the binding of high affinity 
antagonists, such as the SSRIs, without impacting serotonin uptake activity or in vivo 
serotonin clearance (Fig. 4.3A).24-25, 35-36 In Figure 4.3, we show the effects of escitalopram 
on changes in extracellular histamine and serotonin using this mouse. In Figure 4.3Bi and 
ii, escitalopram administration inhibited histamine clearance in Met172 mice (t1/2: control: 
3.65 ± 0.813 s; escitalopram: 5.35 ± 0.31 s; p=0.048) in a manner comparable to wild type 
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mice. These data effectively rule out a role for SERT in histamine clearance or in the 
actions of SSRIs to potentiate extracellular histamine levels but nonetheless show that 
SSRIs inhibit histamine reuptake. In Figure 4.3Ci and ii, we monitored the effects of 
escitalopram administration on extracellular hippocampal serotonin levels and confirmed 
previous findings that escitalopram is ineffective at blocking serotonin clearance in Met172 
mice.24 In wild type mice, escitalopram increased evoked hippocampal serotonin (Ampmax: 
29.19 ± 4.25 nM to 63.30 ± 5.33 nM; p= 0.008) and slowed extracellular clearance (t1/2: 
1.50 ± 0.07 s; 7.98 ± 1.67 s; p=0.03) after 50 min. 
 
Figure 4.3: Histamine reuptake is inhibited by monoamine transporter inhibitors. 
(A) Cartoon schematic depicting SSRIs inability to bind to SERTs and prevent 
serotonin reuptake in Met172 mouse. (B) Evoked hypothalamic histamine control 
(blue) and 50 min post escitalopram (green, 10 mg kg-1) in (i) Met172 and (ii) WT 
mice (n=4, each). (C) Evoked hippocampal serotonin control (grey) and 70+ min 
post escitalopram (red, 10 mg kg-1) in (i) Met172 (n=5) and (ii) WT mice (n=4). 
The grey and green bars represent the electrical stimulation from 5-7 s. Error (± 
standard error of the mean) is a shaded region around traces. 
 
4.4 Discussion 
 Commonly prescribed SSRIs, citalopram, escitalopram, and sertraline all inhibited 
the reuptake of histamine following electrical stimulation (Figure 4.1). In addition to their 
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high affinity for SERT, SSRIs do possess some off-target affinity for OCT.37-38 This is 
particularly important to highlight in terms of antidepressant therapies. Serotonin is thought 
to be decreased in the extracellular space in depressed patients and the goal of 
antidepressants is to return serotonin to a healthy level.39 In fact in the next chapter we 
provide unequivocal evidence for this lowered serotonin level. Studies have documented 
the comorbidity of inflammation and depression40-42 and elevated levels of 
proinflammatory cytokines has spawned a new hypothesis on the underlying causes of 
depression.43 However, pharmacological targeting of inflammatory biomarkers has yielded 
inconsistent results.44-46 Histamine is a peripheral marker of inflammation and in Chapter 
5 we show that histamine is also a maker of neuroinflammation. Given that during 
inflammation (i.e. depression) brain histamine is increased and this histamine is at least 
partially responsible for inhibiting serotonin levels, the compounds ostensibly prescribed 
to alleviate depressive symptoms may in fact have detrimental effects through keeping 
histamine present in the synapse and inhibiting the release of serotonin; antithetical to their 
prescribed role. Antidepressants are prescribed to a substantial percentage of the population 
and patients often take several weeks for symptom alleviation.47 We highlight the critical 
need for a comprehensive understanding of the molecular mechanisms of antidepressants 
to improve clinical efficacy. 
A histamine specific transporter has not yet been identified despite histamine 
having reuptake kinetics similar to other rapidly cleared monoamines and histamine N-
methyltransferase being located intracellularly.13, 18-19 Indeed, in Samaranayake et al. 
where we first described FSCV dual histamine-serotonin measurement, when 
mathematically describing the responses, the models necessitated an active reuptake term 
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to fit the histamine curves.17 Thus, we pharmacologically tested whether inhibition of other 
monoamine transporters affected histamine reuptake. We inhibited SERTs (with three 
different agents), DATs, and NETs and found that SERT and NET inhibition slowed the 
clearance of histamine. Next we turned towards OCTs and PMATs. OCTs and PMATs are 
low affinity transporters with the notable ability to non-selectively transport biogenic 
amines.48-49 Gasser and colleagues recently showed that OCT and PMAT reuptake 
histamine (and other monoamines) with varying affinities.22 Our results are in agreement 
and show that OCT/PMAT inhibition via decynium-22 slowed the clearance of histamine 
in vivo. However, these results do not definitively identify which transporter is responsible 
for histamine reuptake because the different agents we administered have affinity for the 
different monoamine transporters.20 Importantly, we show that histamine clearance was 
inhibited by several compounds that all possess antidepressant activity in Figure 4.1 
(sertraline, escitalopram, citalopram, desipramine, and decynium-22).50-51 
To narrow down a histamine reuptake transporter, we utilized a transgenic mouse 
model, the SERT Met172. SERT Met172 mice are a genetic knock-in strain which bear a 
single amino acid substitution that renders their SERT insensitive to several SSRIs.24, 35-36 
Importantly, this model allows the SERT to remain intact and functioning, which is 
arguably more physiologically relevant rather than removing SERT function entirely as in 
a SERT knockout mouse.35, 52 Using this mouse, we observed that escitalopram no longer 
antagonized serotonin reuptake (Figure 4.3C), yet still slowed histamine clearance, 
strongly suggesting that a transporter other than SERT which escitalopram has affinity for53 
dictates escitalopram-mediated clearance. Moreover, a NET-specific tricyclic 
antidepressant (desipramine) with little SERT activity also delayed histamine clearance. 
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Given the ability of the OCT/PMAT inhibitor decynium-22 to inhibit evoked histamine 
clearance, it seems likely that SERT-independent effects of SSRIs and the tricyclic 
antidepressant may be mediated by these transporters. This is a reasonable assumption 
given that OCTs are located most densely on glial cells that mediate the brain’s immune 
reactions.54-55 
It is important to remember the greater implications of this finding. During 
depression and chronic stress, elevated levels of histamine are contributing to decreased 
serotonin levels through H3 modulation. Antidepressants are prescribed with the intention 
to raise serotonin in the extracellular space and increase receptor activation. However, 
these very prescriptions may result in sustained histamine presence in the synapse 
decreasing overall serotonin levels. Future work should be aimed at mitigating 
antidepressant affinity for OCT and aimed at designing therapeutic targets with 
neuromodulation in mind. 
4.5 Conclusion 
 Histamine is an understudied neuromodulator, but its reuptake mechanism is not 
fully elucidated. We pharmacologically inhibited serotonin transporters (SERT), dopamine 
transporters (DAT), norepinephrine transporters (NET), organic cation transporters (OCT), 
and plasma membrane monoamine transporters (PMAT) and found all agents that inhibited 
histamine clearance exhibited antidepressant effects. We then used the transgenic mouse 
model SERT Met172 to rule out SERT’s contribution to histamine reuptake in the brain. 
Our data are in agreement with the conclusion that high efficiency, low affinity OCT are 
responsible for the bulk of histamine reuptake. PMATs still remain to be studied more 
extensively, but currently the only selective PMAT inhibitors are HIV protease inhibitors 
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and present their own confounding factors. Antidepressants target the different monoamine 
transporters to block reuptake in an effort to extend the amount of time that molecules 
spend in the synapse. However, we have shown evidence that common SSRIs may have 
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Depression is the leading cause of disability worldwide and current treatments are 
variable with even the most efficacious selective serotonin reuptake inhibitors (SSRIs) only 
benefitting ~30% of patients. The low efficacy is in part due to serotonin’s role in 
depression remaining undefined. New research highlights a potential role for inflammation 
in the low efficacy of antidepressants, further stressing the need to understand the complex 
relationship between the brain, serotonin, antidepressants, and inflammation. Here we used 
a chronic mild stress (CMS) paradigm, that is associated with depression phenotypes and 
neuroinflammation. We analyzed the effect of CMS on the neurotransmission of histamine 
and serotonin in the hypothalamus and hippocampus, respectively, with fast 
electrochemical techniques. We found that CMS increased evoked histamine compared to 
age matched control mice and decreased the extracellular levels of hippocampal serotonin. 
Additionally, CMS induced inflammation impaired the ability of escitalopram, an SSRI, to 
raise serotonin levels compared to control. Finally, we co-administered escitalopram with 
a histamine synthesis inhibitor and found that alleviating histamine’s influence on 
serotonin allows for escitalopram to increase serotonin in a similar fashion to non-stressed 
control mice. These results suggest that histamine plays a crucial role in modulating 
serotonin during inflammation and provides a novel therapeutic target as well as insight 
into the neurochemical basis of depression. 
5.1 Introduction 
 Depression is a debilitating disease that presents itself through a myriad of 
symptoms and severities patient to patient.1-3 Rates of depression among the global 
population have been steadily growing in recent decades, one reason being a decreased 
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stigma surrounding mental health diagnoses. Health professionals warned about the 
looming global mental health crisis associated with extensive isolation and feelings of 
hopelessness during the unprecedented worldwide COVID-19.4-5 Despite increased 
prevalence and reduced stigma around depression, treatments have remained stagnant with 
only a few new therapies introduced in the last two decades.6 
 Traditional antidepressants focus on three main monoamine neurotransmitters that 
underpin the monoamine hypothesis of depression – dopamine, norepinephrine, and 
serotonin.7 The theory hypothesizes that one, two, or all of these monoamines are 
dysregulated, and their concentrations are lowered in the synaptic area.8 The majority of 
antidepressants have focused on the serotonergic system, specifically aiming to block the 
reuptake of serotonin through the serotonin transporter (SERT). This class of compounds, 
selective serotonin reuptake inhibitors, has undergone thorough investigation since the 
1970s balancing high affinity for SERT and minimal off-target effects.9 Despite decades 
of research, treatments remain ineffective, with only ~30% of patients responding to their 
first or second prescribed antidepressants and those who do respond typically experience 
several weeks of delayed onset.10 Ultimately, treatment shortcomings stem from the fact 
that there has not been a clearly identified chemical marker for depression that can be 
‘corrected’ to restore a patient’s heath. 
 There is growing evidence that depression and inflammation, specifically 
neuroinflammation, are comorbid but it is unclear which precipitates the other.11-12 
Neuroinflammation is the CNS analogue of peripheral inflammation and is evidenced by 
similar biochemical markers.13-14 What remains unclear during cases of 
neuroinflammation, is how histamine in the brain is reacting to the immune processes. 
 
 91 
Knowing that histamine is able to negatively modulate serotonin release in the brain via 
H3Rs15 and common SSRIs inhibit the reuptake of histamine in the brain (Chapter 4), it is 
critical to understand how histamine behaves in the brain during inflammation. 
Interestingly, a strong link between inflammatory markers in serum and SSRI resistance 
has been identified.16-17 Additionally, antidepressant treatment has been shown to reduce 
inflammation and recent evidence suggests inhibiting proinflammatory cytokines can 
alleviate depressive symptoms18-21 and increase SSRI efficacy.22-23 Studies have suggested 
an important role for brain histamine in antidepressant treatment, therefore, we explored 
this connection between histamine and serotonin during neuroinflammation.24-25 
 In this study, we utilize an established behavior paradigm (unpredictable chronic 
mild stress; CMS) that is known to induce depression-like phenotypes and inflammation 
in mice. 26-29 While we did not find strong significance in the depression phenotypes or 
inflammation markers in these mice, using voltammetry we found that histamine was 
significantly elevated. As such, CMS-treated mice displayed a decreased level of 
extracellular serotonin and an impaired response to SSRI when compared to non-stressed 
controls. We have shown that the CMS-treated mice response to SSRI can be restored when 
histamine’s inhibitory action was eliminated by co-administering a histamine synthesis 
blocker with the SSRI. These results highlight the importance of the histamine system and 
inflammation in the underlying mechanisms of depression. 
5.2 Materials and Methods 
Chemicals and Reagents 
Escitalopram oxalate (10 mg kg-1) (Sigma Aldrich, St. Louis, MO, USA) and α-
fluoromethylhistidine dihydrochloride (20 mg kg-1) (Toronto Research Chemicals Inc., 
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Toronoto, CAN) were individually dissolved in sterile saline (0.9% NaCl solution, 
Hospira, Mountainside Medical Equipment, Marcy, NY, USA) and administered via 
intraperitoneal (ip) injection at a volume of 5 mL kg-1 body weight. Urethane (Sigma 
Aldrich, St. Louis, MO, USA) was dissolved in sterile saline at 25% w/v and administered 
at 7 µL/g mouse body weight for surgical anesthesia. 
Calibration solutions were prepared by dissolving serotonin hydrochloride (Sigma 
Aldrich, St. Louis, MO, USA) in Tris buffer to produce solution concentration of 10, 25, 
50, and 100 nM. Tris buffer consisted of 15 mM H2NC(CH2OH)2 HCl, 140 mM NaCl, 3.25 
mM KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4 H2O, 1.2 mM MgCl2, and 2.0 mM Na2SO4 
(Sigma Aldrich, St. Louis, MO, USA) in deionized water and pH adjusted to 7.4. 
Electrode Fabrication 
 All electrodes are made in house. A single carbon fiber is aspirated into a 
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim 
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige, 
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is then 
trimmed under light microscope to ~150 µm by scalpel. An electrical connection is forged 
with the fiber through a stainless-steel connecting wire and silver epoxy. Finally, a thin 
layer of Nafion (LQ-1105, Ion Power, New Castle, DE, USA) is electrodeposited onto the 
fiber surface at 1 V for 30 s; the coated fiber is dried for 10 min at 70 °C.15, 30 
Data Collection and Analysis 
 Fast-scan cyclic voltammetry and fast-scan controlled adsorption voltammetry 
(FSCAV)  were performed on anesthetized mice using a Dagan potentiostat (Dagan Corp., 
Minneapolis, MN, USA) and custom built hardware interfaced with PCIe 6341 & PCI 6221 
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DAC/ADC cards (National Instruments, Austin, TX) and a Pine Research headstage (Pine 
Research Instruments, Durham, NC, USA). WCCV 3.06 software (Knowmad 
Technologies LLC, Tucson, AZ, USA) was used to control the hardware and perform data 
analysis. For FSCV collection, the “Jackson” serotonin waveform31 was applied at 60 Hz 
for 10 min, then at 10 Hz for 10 min prior to data collection or the histamine waveform (-
0.5 V to -0.7 V to +1.1 V to -0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 
10 Hz for min prior to data collection. Data were collected at 10 Hz. Neurotransmitter 
release was evoked via biphasic stimulation applied through a linear constant current 
stimulus isolator (NL800A Neurolog, Digitimer North America LLC, Fort Lauderdale, FL, 
USA) with stimulations at 60 Hz, 360 µA, 2 ms in width, and 2 s in length. 
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3 
kHz low pass filter for histamine; 5kHz low pass filter for serotonin). For FSCV analysis, 
the cyclic voltammogram (CV) was used to identify histamine and serotonin and the 
current vs. time (IT) was extracted to visualize release and reuptake. Currents obtained 
were converted to concentrations through previously generated calibration factors for both 
histamine (2.825 µM nA-1) and serotonin (11 µM nA-1)15, 32 and hippocampal serotonin 
(49.5 ± 10.2 nA/µM).30 
For basal experiments, control evoked files were collected followed by the 
methodology being switched to FSCAV. FSCAV was performed using a CMOS precision 
analog switch, ADG419 (Analog Devices). For FSCAV collection, the serotonin waveform 
was applied at 100 Hz for 2 s followed by a period of controlled adsorption where the 
potential was held at 0.2 V for 10 s and then the serotonin waveform was reapplied at 100 
Hz, as described in Abdalla et al.33 Thirty files (at one file min-1) were collected as control 
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files. Following control files, an ip injection of saline was administered and 30 more files 
of FSCAV were collected. Animals were then administered escitalopram (10 mg kg-1; ip) 
and 60 files post-escitalopram were collected. The system was then switched back to 
traditional FSCV and four post-basal stimulation files were collected. Electrodes were 
removed from the animal and underwent post-calibration in which 10 files were collected 
with the electrode in solutions of 10, 25, 50, and 100 nM serotonin. 
For FSCV data, four IT curves were averaged for each animal to establish a control 
signal. The average for each individual animal was then averaged throughout the group to 
create an overall group average. 
For FSCAV data, the first characteristic CV following waveform reapplication was 
selected for quantification, and the peak occurring approximately between 0.4 and 0.85 V 
was integrated to determine the charge (pC). Post-calibrations of each electrode, plotting 
charge (pC) vs. [serotonin] (nM), were used to determine basal concentration. 
Statistical Analyses 
 Exclusion criteria were based on outliers (via Grubbs test) and animals that did not 
survive the experimental paradigm. To determine the t1/2, a code was custom written in 
Excel to fit the reuptake component of the curve and calculate the time taken to reach half 
the maximum amplitude. Standard error of the mean (SEM) was calculated using the 
average response of each animal (n = # animals). Significance between two points was 
determined by 2-tailed paired t-test and taken as p < 0.05. Two-way ANOVA was used to 
determine significance between control max amplitude and the time course of drug max 
amplitude. All error bars represent the standard error of the mean (SEM). Area under the 
curve (AUC) was measured using Simpson’s rule of histamine release from time 0 s to the 
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first intercept of the x axis; in the case of two peaks, only the first peak was analyzed. The 
Shapiro-Wilk test was used to determine AUC data distribution. The Wilcoxon rank-sum 
test was applied between control and CMS. Significance was taken as p<0.05. 
Animals and Surgical Procedure 
 Animal procedures and protocols were in accordance with the regulations of the 
Institutional Animal Care and Use Committee (IACUC) at the University of South 
Carolina, accredited through the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). Male and female C57BL/6J mice (Jackson 
Laboratory, Bar Harbor, ME, USA) arrived at 6-7 weeks old group housed, with ad libitum 
access to food and water, and were kept on a 12 h light/12 h dark cycle (lights off 0700; 
light on 1900). An unpredictable chronic mild stress (CMS) paradigm was conducted over 
a 16-week period and based on previously documented models.34-37 Two to three mild 
stressors were performed a day. Stressors included: food or water deprivation, 
confinement, cage tilt, soiled cage, light during dark cycle, bedding removal, novel object, 
and handling. All stressors were stopped during behavior testing and 12 h leading up to 
neurochemical studies. 
 Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed 
induction of deep and sustained anesthesia from an ip injection of urethane. Mouse body 
temperature was maintained using a thermal heating pad (Braintree Scientific, Braintree, 
MA, USA). All surgical coordinates were taken in reference to bregma.38 For serotonin 
analysis, a Nafion coated CFM was lowered into the CA2 region of the hippocampus (AP: 
-2.91, ML: +3.35, DV: -2.5 to -3.0) and a stimulating electrode (insulated stainless-steel, 
diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial 
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forebrain bundle (AP: -1.58, ML: +1.00, DV: -4.8). For histamine analysis, a Nafion coated 
CFM was lowered into the posterior hypothalamus (AP: -2.45, ML: 0.50, DV: -5.45 to -
5.55) and a stimulating electrode was placed into the medial forebrain bundle (AP: -1.07, 
ML: +1.10, DV: -5.00). A pseudo-Ag/AgCl reference electrode, created by chloridizing a 
polished silver wire in HCl (15 s in 1 M HCl at 5 V), was placed in the contralateral 
hemisphere.  
Behavioral Analyses 
Following the CMS behavioral paradigm, mice underwent behavioral testing for 
anxiety- and depressive-like phenotypes. Sucrose preference test (SPT) was conducted as 
previously described.39 Briefly, mice were given access to water and 1% sucrose solution 
for 24 h and the difference in consumption amounts was recorded. Elevated zero maze 
(EZM) was conducted as previously described.40 Each mouse was placed into the closed 
arm of the apparatus (Maze Engineers, Boston, MA, USA) and allowed to explore for 5 
min. Time spent in the closed arm was measured as an indicator of anxiety-like behavior. 
Tail suspension test (TST) was completed as previously described.41 Mice were attached 
via tape to a supported metal rod and a small plastic, flexible tube was placed on the tail to 
limit climbing behavior within the apparatus (Maze Engineers, Boston, MA, USA) for the 
duration of the 6 min test. Percent immobility was measured in the first two min (as pre-
test) and the remaining 4 min (test period) as an indicator of depressive-like behavior. 
Forced swim test (FST) was conducted as previously described.42 Briefly, mice were 
individually placed in 4 L beakers filled with ~30 °C water for 5 min and the latency to 




BioPlex immunoassays (Bio-Rad Laboratories, Hercules, CA, USA) were used according 
to manufacturer instructions to analyze cytokines in plasma at sacrifice. 
5.3 Results 
5.3.1 Behavioral and cytokine analyses 
Following the stress paradigm, we analyzed behavioral tests for anxiety (elevated 
zero maze) and depression through SPT, TST and FST. For the SPT (Figure 5.1B), 
significantly less preference was only found in male mice after 12 h (control: 88.31 ± 
0.92%; CMS: 83.33 ± 1.42%; p= 0.013). For the EZM (Figure 5.1C), CMS-treated mice 
spent significantly more time in the closed arm of the maze than control mice (249.83 ± 
2.76 s, 230.09 ± 3.79 s respectively; p < 0.001). For the FST, only male mice showed less 
active behaviors after CMS (Con: 41.36 ± 8.05%; CMS: 66.14 ± 9.13%; p=0.035) (Figure 
5.1D). There were no significant differences between control and CMS mice in the TST 
despite a clear trend (65.64 ± 4.17 %, 70.50 ± 3.57 % respectively; p = 0.38) (Figure 5.1E). 
While there is some significance in this data, in our hands CMS does not robustly (i.e. in 
every animal) create depression-like phenotypes. 
Similarly, we performed plasma cytokines analyses from these mice and found that 
differences were weakly significant. There was no difference in peripheral cytokine 
concentration between these two groups, however, when the ratios of proinflammatory 
cytokines to anti-inflammatory cytokines were compared, for example with TNF- / IL-4 
in females, significance was apparent (control: 15.18 ± 0.93 pg/mL; CMS: 19.30 ± 1.30 
pg/mL; p = 0.016) (Figure 5.1F). CMS-treated mice also trended towards an increase in 
IL-6/IL-4 ratios (p =0.21 and 0.24 in male and female mice) (Figure 5.1F). Overall, 
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Figure 5.1: Behavioral and inflammatory changes following CMS 
treatment. (A) A schematic is shown for the 16-week CMS 
paradigm used as well as behavior, neurochemical, and 
inflammation studies that followed. (B) Average sucrose preference 
(sucrose water consumed - water consumed / total water consumed) 
in the SPT for non-stress control (bue; n=40) and CMS (gray; n=39) 
mice (t-test, p <0.001). (C) Average time spent in the closed sections 
of the EZM is shown for control (blue; n=37) and CMS (gray; n=36) 
mice. (D) Average percentage of time immobile in the FST for male 
(blue) and female (light blue) control mice and male (gray) and 
female (light gray) CMS mice. (E) Average percentage of time 
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immobile in the TST is shown for control (blue) and CMS (gray) 
mice. (F) Analysis of cytokine ratios (TNF-/IL-4 and IL-6/IL4 
respectively). Significance was defined as p < 0.05 in a student’s t-
test. 
 
5.3.2 Hippocampal serotonin is decreased in CMS mice 
In these mice we next measured evoked and ambient serotonin with fast-scan cyclic 
voltammetry (FSCV) and fast-scan controlled adsorption voltammetry (FSCAV). We 
developed these tools in our lab for minimally invasive, highly reproducible serotonin 
measures on the neurotransmission temporal and spatial scale. There was no difference in 
evoked serotonin in the hippocampus between control and CMS mice (Ampmax: Control: 
19.02 ± 3.2 nM; CMS: 19.29 ± 3.71 nM; p = 0.804) or reuptake of serotonin (t1/2: Control: 
2.31 ± 0.27 s; CMS: 2.29 ± 0.26 s; p = 0.953) (Figure 2A-E). However, using FSCAV we 
were able to show a robust difference in basal or ambient serotonin. In this region (Figure 
2F-H), every single mouse that underwent the chronic stress paradigm had decreased 
ambient serotonin (Cmax: control: 63.17 ± 2.67 nM, CMS: 46.70 ± 0.72 nM; t-test, p <0.001), 
despite weakly correlated behavioral and cytokine analysis. 
5.3.3 Hypothalamic histamine is increased in CMS mice 
Fast-scan cyclic voltammetry analysis of histamine was performed in the posterior 
hypothalamus of the mice. In Figure 5.3A, a representative FSCV color plot is shown. The 
[HA] vs time and [5HT] vs time is shown in Figure 5.3B for non-stressed control (blue) 
and CMS-treated mice (green). There was no apparent change in the reuptake of histamine 
between CMS and non-stressed control mice (t1/2: control: 2.5 ± 0.7 s; CMS: 3.2 ± 0.6 s; 
p=0.23) The peak inhibition of serotonin following histamine release was increased in 
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CMS mice, however this effect was not significant (Ampmax: control: 24.02 ± 6.30 nM; 
CMS: 26.34 ± 4.32 nM; p=0.77). 
 
 
Figure 5.2: Decreased extracellular serotonin predicts stress. (A,C) 
Example 5HT color plots from control and CMS mice respectively. (B,D) 
Example 5HT cyclic voltammograms from control and CMS mice 
respectively. (E) Evoked hippocampal serotonin in control (blue) and 
CMS (gray) mice. (F) An example of a basal serotonin color plot. (G) An 
example of a basal serotonin cyclic voltammogram from which basal 
serotonin was calculated using the equation shown (τ = Surface 
Concentration, Q = Charge, n = Charge on the Molecule, F = Faraday 
Constant, and A = Surface Area). (H) Average basal serotonin in control 
(blue) and CMS (gray) mice is shown in a bar graph and individual 
animals are denoted by circles. Error is shown as SEM and a student’s t-




Figure 5.3 Chronic mild stress treatment elevates histamine. (A) 
Representative color plot of evoked histamine and serotonin inhibition with 
an inset cyclic voltammogram confirming the electrochemical identities of 
histamine and serotonin. The blue bar represents electrical stimulation from 
5 - 7 s. (B) Average CMS (green, n=5) and non-stressed control (blue, n=6) 
evoked [histamine] and [serotonin] inhibition vs time profiles. Error (± 
standard error of the mean) is shown as the shaded region around traces. 
 
 We hypothesized that the serotonin levels in CMS mice are low due to elevated 
histamine in the hypothalamus Figure 5.3B, thus, we tested this notion and found in CMS 
mice there is a non-significant increase in histamine release (control: 4.28 ± 0.51 M; 
CMS: 5.64 ± 0.66 M; p=0.13) and a significant increase in area under the curve of 
histamine release (AUC control: 14.51 ± 2.35 µM•s; CMS: 25.50 ± 2.80 µM•s; Wilcoxon 
rank-sum test, p=0.02) (Figure C1). 
The increased histamine explains the decreased ambient serotonin seen in Figure 
5.2H. Therefore, we designed an experiment in which three groups of animals would 
receive escitalopram under different treatments: non-stressed control (escitalopram; 10 mg 
kg-1), CMS mice (escitalopram; 10 mg kg-1), and CMS mice co-administered escitalopram 




Figure 5.4: Dual targeting of histamine and serotonin effects on 
hippocampal serotonin in CMS-treated mice. Basal serotonin measurements 
are shown for control mice given saline and then escitalopram (ip, 10 mg 
kg-1, n=5, blue), CMS-treated mice given saline and then escitalopram (ip, 
10 mg kg-1, n=5, grey), and CMS-treated mice given saline and then 
escitalopram (ip, 10 mg kg-1) and FMH (ip, 20 mg kg-1, purple, n=5). 
 
5.4 Discussion 
5.4.1 Brain Serotonin is Lower in Response to Chronic Inflammation 
 The CMS treatment protocol is a model to induce depression-like phenotypes in 
rodents that also results in associated neuroinflammation.26-29 Therefore, we used this 
model to induce chronic inflammation in a cohort of mice to study the effects on brain 
serotonin and histamine levels. While we found weak significance between this paradigm 
and depression-like phenotypes and inflammation, using FSCV and FSCAV, developed in 
our lab, to measure serotonin we found that CMS-treated mice exhibited a significantly 
lower amount of ambient serotonin in the brain compared to control (Figure 5.4). This 
phenomenon has been hypothesized and studied for some time.43-44 CMS has been said to 
decrease brain serotonin levels45-47, a finding that has also been contradicted48 while acute 
stress has been shown to increase serotonin.49-50 Importantly, CMS has also been associated 
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with chronic inflammation.27, 51 Thus, agreement had not been reached in the community 
about whether serotonin levels were actually lower during depression. Here for the first 
time, we show that stress robustly decreases serotonin. Knowing histamine’s modulatory 
control of serotonin, we next aimed to determine if histamine is altered in CMS-treated 
mice. 
5.4.2 Brain Histamine is Elevated during CMS Induced Neuroinflammation 
Behaviorally depressed mice had higher levels of evoked histamine as analyzed by 
fast scan cyclic voltammetry (Figure 5.3/C1). We contribute our small sample size to 
unfortunate animal loss as behaviorally depressed mice are known to respond poorly to 
anesthesia.52-54 Histamine has been shown to be a crucial signaling molecule for the 
immune system55-56 and the connection between depression and altered immune system 
functionality has been explored.57 Activated microglia and mast cells can regulate local 
levels of histamine, which directly respond to immune reactions within the brain.58-62 
Additionally, microglia and mast cell activation is thought to be linked to the induction of 
anxiety and stress behaviors through inflammatory signaling.63-65 The role of histamine in 
inflammatory communication in the brain has not yet been definitively determined, but 
regulation appears to be complimentary in that histamine receptors can also affect cell 
recruitment66-67 Here, we have shown that CMS-induced neuroinflammation increased 
histamine and decreased serotonin levels in the brain. Previously, we showed that this 
inverse modulation of histamine on serotonin was due to activation of H3 receptors present 




5.4.3 Dual pharmacological targeting of serotonin and histamine restores SSRI efficacy 
during chronic inflammation 
Our measurements of serotonin and histamine are in two distinctly different brain 
regions, the hippocampus and the hypothalamus. We hypothesized that elevated 
inflammation (thus elevated basal histamine levels) could mediate the lower extracellular 
levels of serotonin observed in the hippocampus. We intended to remove the inhibitory 
effect of histamine on H3 heteroreceptors on serotonin terminals to observe whether we 
could return serotonin levels to pre-stress levels. Employing an antihistamine is enticing 
but as covered in Chapter 3, those agents target post-synaptic H1 and H2, not H3 receptors, 
and actually would result in sustained extracellular histamine. In fact, H3R are not the ideal 
pharmacological targets either as administering an agonist or antagonist would have 
confounding effects (immepip or thioperamide; Chapter 3). Thus, we chose to globally 
lower histamine levels by inhibiting the overall synthesis of histamine. We accomplish this 
through α-fluoromethylhistidine (FMH), a suicide inhibitor of histidine decarboxylase 
(sole enzymatic route of histamine synthesis). Studies have shown this compound 
dramatically decreased both peripheral and central histamine.68-70 Co-administration of 
escitalopram and FMH induced robust increases in ambient serotonin (Figure 5.4). We 
postulated that dual targeting of histamine and serotonin could increase extracellular 
serotonin and ameliorate the impaired SSRI-induced increases in serotonin seen in CMS-
treated mice. In CMS-treated mice, we observed ambient serotonin increased faster and to 
a level comparable to control mice receiving escitalopram. Importantly, we suggest that 





 Depression and inflammation are two inextricably linked phenomena that cause 
debilitating effects in patients. We used an unpredictable chronic mild stress paradigm to 
induce a depression-like phenotype and associated neuroinflammation in mice. We have 
shown that serotonin levels are functionally lowered in chronically stressed mice and 
confirm the notion that brain histamine levels are elevated during neuroinflammatory states 
using in vivo fast-scan cyclic voltammetry. We postulated that elevated histamine is at least 
partially responsible for decreased serotonin as we were able to restore escitalopram’s 
ability to increase hippocampal serotonin in the absence of histaminergic control. Our 
results highlight the importance of considering the histaminergic system and the role it 




AN IN VIVO ANALYSIS OF KETAMINE’S HISTAMINERGIC 
MODULATION OF SEROTONIN IN THE POSTERIOR 
HYPOTHALAMUS1
 
1 Berger, SN., Witt, CE., Baumberger Altirriba, BM., Hashemi, P. An in vivo analysis of 
ketamine’s histaminergic modulation of serotonin in the posterior hypothalamus. In 




Ketamine is a dissociative anesthetic that has recently been highlighted for its 
potential role as a rapid acting antidepressant in patients with major depressive and 
treatment resistant depression. Despite the clinical rush to approve a treatment paradigm 
utilizing ketamine, a large portion of ketamine’s antidepressant effects remain unknown. 
We used fast voltammetric methods to investigate ketamine’s effects on monoamine 
transmission in the hypothalamus and hippocampus of mice. We found ketamine caused a 
robust decrease in electrically evoked histamine in the hypothalamus and increased 
ambient serotonin levels in the hippocampus. We attributed these results to activation of 
metabotropic glutamate receptors 2 & 3 and glutamatergic modulation of monoamine 
transmission. Our data reveal new biochemical impacts of ketamine on the brain and will 
aid in understanding ketamine’s antidepressant mechanisms. 
6.1 Introduction 
Ketamine is an important anesthetic, used primarily in veterinary medicine and 
recognized as an essential medicine by the World Health Organization.1 Ketamine has 
recently been proposed as a new sensational treatment for major depressive disorder 
despite its storied history as a recreational drug of abuse.2 While the clinical data on 
ketamine treatment seems to show net positive effects on patients’ outcomes, benefits have 
variable duration and require repeated injections.3-9 Exactly how ketamine exerts its effects 
remains unknown. Ketamine is functionally different than ‘classical’ antidepressants in 
that it doesn’t directly target one of the major monoaminergic systems eg. dopamine, 
serotonin, or norepinephrine. Acting mainly as an N-methyl-D-aspartate (NMDA) receptor 
antagonist, ketamine’s primary effects are on the glutamatergic and GABAergic systems. 
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A substantial body of work has been dedicated to teasing apart which functional changes 
are responsible for ketamine’s antidepressant effects. Metabolism of (R/S)-ketamine to 
(2R,6R;2S,6S)-hydroxynorketamine appears to be essential for antidepressant effects.10 
Interestingly, the S enantiomer is the more potent inhibitor of the NMDA receptors while 
the R enantiomer metabolite appears significantly responsible for antidepressant effects 
without the psychosis associated with the S enantiomer.11-12 These results, in conjunction 
with the low clinical efficacy found in clinical trials, are curious considering the recent 
Food and Drug Administration (FDA) approval of Johnson & Johnson’s Spravato, which 
is an enantiomerically pure S-ketamine nasal spray.13 
Much of the focus on understanding ketamine’s antidepressant effects has centered 
around glutamate, GABA, and serotonin. Based on the known comorbidity of depression 
and inflammation, in this work, we explored the role that histamine plays in this emerging 
depression treatment. We previously observed that common selective serotonin reuptake 
inhibitors (SSRIs) inhibit the reuptake of histamine from the synaptic cleft (Chapter 4) 
and histamine levels are elevated in behaviorally depressed mice (Chapter 5). Histamine 
remains an understudied molecule in the context of depression, therefore, our goal was to 
expand the understanding of ketamine’s effects on the central nervous system by 
monitoring how hypothalamic histamine responded to a sub-anesthetic dose of ketamine. 
Additionally, we analyzed how the modulation of serotonin via histamine was altered 
following ketamine exposure. We found that systemic administration of ketamine causes 
rapid and sustained inhibition of hypothalamic histamine and attenuates histaminergic 
inhibition of serotonin. As such, ketamine increases the ambient levels of serotonin in a 
manner synonymous to standard SSRIs. Our results highlight critical mechanistic 
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differences between rapid-acting and slow-acting antidepressants on key neurotransmitter 
systems. 
6.2 Methods and Materials 
Chemicals and Reagents 
 Ketamine hydrochloride (Vet One, MWI Animal Health, Boise, ID, USA) and 
escitalopram oxalate (Sigma Aldrich, St. Louis, MO, USA) were individually dissolved in 
sterile saline (0.9% NaCl solution, Hospira, Mountainside Medical Equipment, Marcy, 
NY, USA) and administered via intraperitoneal injection at 10 mg kg-1 and a volume of 5 
mL kg-1 body weight. Urethane (Sigma Aldrich, St. Louis, MO, USA) was dissolved in 
sterile saline at 25% w/v and administered at 7 µL/g mouse body weight for surgical 
anesthesia. 
Electrode Fabrication 
All electrodes are made in house. A single carbon fiber is aspirated into a 
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim 
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige, 
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is then 
trimmed under light microscope to ~150 µm by scalpel. An electrical connection is forged 
with the fiber through a stainless-steel connecting wire and silver epoxy. Finally, a thin 
layer of Nafion (LQ-1105, Ion Power, New Castle, DE, USA) is electrodeposited onto the 
fiber surface at 1 V for 30 s; the coated fiber is dried for 10 min at 70 °C.14-16 
Data Collection and Analysis 
Fast-scan cyclic voltammetry was performed on anesthetized mice using a Dagan 
potentiostat (Dagan Corp., Minneapolis, MN, USA), WCCV 3.06 software (Knowmad 
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Technologies LLC, Tucson, AZ, USA), and a Pine Research headstage (Pine Research 
Instruments, Durham, NC, USA). The histamine waveform (-0.5 V to -0.7 V to +1.1 V to 
-0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 10 Hz for min prior to data 
collection. Data were collected at 10 Hz. Histamine was evoked via biphasic stimulation 
applied through a linear constant current stimulus isolator (NL800A Neurolog, Digitimer 
North America LLC, Fort Lauderdale, FL, USA) with stimulations at 60 Hz, 360 µA, 2 ms 
in width, and 2 s in length.  
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3 
kHz low pass filter). Four control evoked files, 10 min apart, were averaged for the control 
evoked histamine signal after which ketamine was administered and files were collected at 
0 min, 5 min, 10 min, and every 10 min thereafter until 100 min. Currents obtained were 
converted to concentrations through previously generated calibration factors for both 
histamine (2.825 µM nA-1) and serotonin (11 µM nA-1).15-16 
For basal experiments, control evoked files were collected followed by the 
methodology being switched to FSCAV. For FSCAV collection, the serotonin waveform 
was applied at 100 Hz for 2 s followed by a period of controlled adsorption where the 
potential was held at 0.2 V for 10 s and then the serotonin waveform was reapplied at 100 
Hz, as described in Abdalla et al.17 Thirty files (at one file min-1) were collected as control 
files. Following control files, an ip injection of saline was administered and 30 more files 
of FSCAV were collected. Animals were then administered escitalopram (10 mg kg-1) ip 
and 60 files post-drug were collected. The system was then switched back to traditional 
FSCV and four post-basal stimulation files were collected. Electrodes were removed from 
the animal and underwent post-calibration in which 10 files were collected with the 
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electrode in solutions of 10, 25, 50, and 100 nM serotonin. For FSCAV data, the first 
characteristic CV following waveform reapplication was selected for quantification, and 
the peak occurring approximately between 0.4 and 0.85 V was integrated to determine the 
charge (pC). Post-calibrations of each electrode, plotting charge (pC) vs. [serotonin] (nM), 
were used to determine basal concentration. 
Statistical Analyses 
Average control response was generated from four current vs time traces per animal 
and averaged to create an overall group average. Exclusion criteria were based on outliers 
(via Grubbs test) and animals that did not survive the experimental paradigm. Standard 
error of the mean (SEM) was calculated using the average response of each animal (n = # 
animals). Significance between two points was determined by 2-tailed paired t-test and 
taken as p < 0.05. 
Animals and Surgical Procedure 
Animal procedures and protocols were in accordance with the regulations of the 
Institutional Animal Care and Use Committee (IACUC) at the University of South 
Carolina, accredited through the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). Male and female C57BL/6J mice (Jackson 
Laboratory, Bar Harbor, ME, USA) 8-14 weeks of age weighing 20 to 29 g were used.  
 Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed 
induction of deep and sustained anesthesia from an intraperitoneal injection of urethane 
(below). Mouse body temperature was maintained using a thermal heating pad (Braintree 
Scientific, Braintree, MA, USA). All surgical coordinates were taken in reference to 
bregma.18 A Nafion coated CFM was lowered into the posterior hypothalamus (AP: -2.45, 
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ML: 0.50, DV: -5.45 to -5.55) and a stimulating electrode (insulated stainless-steel, 
diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial 
forebrain bundle (AP: -1.07, ML: +1.10, DV: -5.00). A pseudo-Ag/AgCl reference 
electrode, created by chloridizing a polished silver wire in HCl (15 s in 1 M HCl at 5 V), 
was placed in the contralateral hemisphere.  
6.3 Results 
 Administration of 10 mg kg-1 ketamine ip resulted in a significant decrease in the 
overall amplitude of stimulated hypothalamic histamine (n=5; 2 male, 3 female; Ampmax: 
control: 8.92 ± 1.80 µM; ketamine: 6.09 ± 1.61 µM; p = 0.005) while having no effect on 
the clearance rate (t1/2: control: 4.1 ± 1.1 s; ketamine: 3.3 ± 0.8 s; p = 0.23) after 10 min 
(Figure 6.1B). 
 
Figure 6.1: Ketamine caused rapid inhibition of histamine release and 
alleviates serotonin inhibition. (A) Representative color plot of stimulated 
histamine and serotonin inhibition. Inset: CV showing oxidation peaks of 
histamine and serotonin. (B) Top: evoked histamine control (blue, n=5) and 
10 min following 10 mg kg-1 ketamine (green, n=5) (Ampmax: control: 8.92 ± 
1.80 µM; ketamine: 6.09 ± 1.61 µM; p=0.005 paired t-test). Bottom: 
[serotonin] vs time profiles for control (purple, n=5) and 10 min following 
10 mg kg-1 ketamine (yellow) (Ampmax: control: 44.70 ± 7.91 nM; ketamine: 
20.12 ± 4.88 nM; p=0.013 paired t-test). Error (± standard error of the mean) 




 Ketamine administration had a rapid and sustained effect on suppressed histamine 
release and alleviated serotonin inhibition throughout the duration (100 min) of data 
collection (Figure 6.2A,B) 
 
Figure 6.2: Ketamine caused prolonged suppression of histamine 
release and serotonin inhibition. (A) Control evoked histamine 
maximum amplitude (blue) and max amplitude for minutes 5, 10, 20, 
to 100 min (green) following 10 mg kg-1 ketamine. (B) Control 
serotonin inhibition minimum amplitude (purple) and inhibition 
amplitude for minutes 5, 10, 20, to 100 min (yellow) following 10 mg 
kg-1 ketamine. Error bars represent ± standard error of the mean. 
 
There was no significant change in the reuptake curves (t1/2) of histamine control 
(blue) or post-ketamine (green). Due to the inhibition profile of serotonin post-ketamine, it 
was challenging to determine the reuptake kinetics associated with it. Qualitatively, it can 
be seen that the overall amplitude of serotonin following ketamine is similar to the post-
inhibition (~25 s mark) amount in control signals. 
We next investigated ketamine’s effect on ambient hippocampal serotonin. Control 
serotonin levels were collected for 30 min prior to vehicle (saline; 30 to 60 min) injection. 
Ketamine (blue; 0.66 nM/min) raised extracellular serotonin rapidly following ip 
administration (60 to 120 min) in a similar fashion to escitalopram (orange; 0.482 ± 0.057 
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nM/min), a classical antidepressant that inhibits the serotonin transporter. Saline vehicle 
did not have an effect on serotonin for either compound (escitalopram, n=10 ; control: 
63.68 ± 3.00 nM; saline: 63.53 ± 3.21 nM; p=0.68) (ketamine, n=2; control: 60.03 nM; 
saline: 59.34 nM). Ketamine increased extracellular serotonin 60 min following injection 
(control: 60.03 nM to 94.49 nM) similar to how escitalopram increased serotonin levels 
(control: 63.68 ± 3.00 nM to 91.27 ± 4.64 nM). 
 
Figure 6.3: Ketamine elevated ambient serotonin similar to escitalopram. 
FSCAV data for mice receiving escitalopram (ip; 10 mg kg-1, orange, n=10) 
or ketamine (ip; 10 mg kg-1, blue, n=2). Ambient serotonin concentration is 
collected for 30 min, followed by 30 min of vehicle (saline), followed by 
administration of ketamine (blue) or escitalopram (orange) for 60 min. 
Ketamine (blue; 0.66 nM/min) raised extracellular serotonin rapidly 
following ip administration (60 to 120 min) in a similar fashion to 




We have shown that administration of ketamine (10 mg kg-1; ip) caused rapid and 
sustained inhibition of histamine release in the mouse posterior hypothalamus. Ketamine 
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has not been shown to act directly on the histaminergic system, but most likely regulates 
histamine through glutamatergic and GABAergic routes. GABAergic transmission is 
inhibited by ketamine through NMDA receptor antagonism which leads to excess 
glutamate release. The presence of histamine and GABA in tuberomammillary nucleus 
neurons has been confirmed through immunohistochemistry19 and endogenous GABA has 
been shown to modulate the release of histamine in the hypothalamus.20 Excess glutamate 
release has been shown to influence the release of histamine and activate TMN neurons 
which express both AMPA and NMDA receptors.21 NMDA receptor antagonists increased 
the synthesis and turnover of histamine, which already occurs more frequently than other 
monoamines in the brain.22-23 Infusions of glutamate in the anterior hypothalamus resulted 
in a 150% increase in histamine with respect to baseline measured by microdialysis.24 
Okakura et al. noted that glutamate-evoked histamine release was completely blocked by 
the NMDA receptor specific antagonist AP5, and AP5 alone reduced histamine release to 
around 60% of basal levels.24 These results are in agreement with our data in that ketamine 
caused a robust decrease in histamine release. Fell et al. reported that pretreatment with the 
mGlu2 receptor agonist, LY379268, significantly attenuated histamine release and 
concluded that hypothalamic histamine is modulated by glutamate through mGlu2 
receptors.25-26 Glutamate is a highly potent endogenous agonist of mGlu2 receptors.27-28 
The mGlu2 are located both pre- and post-synaptically and function as auto- and 
heteroreceptors controlling the release of glutamate, GABA and other neurotransmitters.29 
The control of histamine release through glutamate activation of mGlu2/3 is a likely effect 
from ketamine administration. Indeed, immunostaining has confirmed mGlu2 presence in 
the premammillary nucleus30 and mGlu3 presence in TMN.30-31 
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The antidepressant effects of ketamine are thought to stem from synaptic plasticity 
as a result of glutamate activated AMPA (alpha-amino-3-hydroxy-5-methyl-4-
isoxazoepropionic acid) receptors, increased BDNF (brain derived neurotrophic factor), 
activation of mTOR (mammalian target of rapamycin), inhibition of glycogen synthase 
kinase-3 or likely a combination of each.32-34 The importance of mTOR activation is 
disputed as Li et al. reported inhibition of mTOR signaling blocked ketamine’s 
antidepressant effects35 while Abdallah et al. recently reported that rapamycin pretreatment 
(the inhibitor of mTOR) actually prolonged the antidepressant effects of ketamine for 2 
weeks following initial ketamine treatment.36 The antagonism of NMDARs is not required 
for antidepressant effects, but rather an increased level of cyclic adenosine monophosphate 
(cAMP) that results in increased expression of BDNF.37-38 Activation of the AMPA 
receptor is also thought to play an important role in the therapeutic effects of ketamine 
through increased activation of mTOR, part of a signaling pathway that results in increased 
BDNF that then increases synaptic plasticity.39 Antagonism of AMPA receptors 
significantly blocked the beneficial effects of ketamine in rodents undergoing learned 
helplessness, tail suspension, and forced swim tests (tests of depressive-like phenotypes).40-
41 The perisynaptically located metabotropic glutamate receptors 2&3 (mGlu2/mGlu3) 
have also been highlighted for their role in the therapeutic effects of ketamine.42-43 2R,6R-
hydroxynorketamine functions as an antagonist of mGlu2/3 receptor.44 A combination of 
ketamine and an mGlu2/3 receptor antagonist was shown to activate serotonin neurons in 
the dorsal raphe nucleus.45 
In addition to its anesthetic and antidepressant properties, ketamine bears analgesic 
and anti-inflammatory effects. Ketamine’s ability to modulate the body’s immune response 
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arose from observations of improved outcomes in critically ill patients46 and experimental 
septic shock.47 Ketamine has been shown to mitigate the inflammatory challenge of 
lipopolysaccharide and decrease the production of pro-inflammatory cytokines during 
immune response.48-51 The immunomodulatory role of ketamine was reviewed thoroughly 
by De Kock and colleagues.52 In Chapter 5 we covered the influence of chronic mild stress 
and neuroinflammation on brain histamine. In a similar chronic stress behavior model, 
ketamine (10 mg kg-1) induced a rapid antidepressant effect and decreased expression of 
hippocampal proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor 
alpha (TNFα).53 Interestingly, ketamine’s inflammatory response may be dose dependent 
as higher doses (50 mg kg-1 and above) have been shown to increase expression of 
inflammatory proteins.54-55 Antidepressant benefits of ketamine involve sub-anesthetic 
doses, therefore, the increased inflammatory signaling observed with high doses of 
ketamine will generally not be expected.56 Overall, ketamine’s anti-inflammatory effects 
function as a pretreatment to immune challenge rather than a response49 and ketamine has 
no effect on cytokine production without an immune stimulus.52 
We have shown that ketamine caused a robust and persistent decrease in evoked 
histamine. Ketamine has been shown to elevated glutamate transmission while also 
functioning as an anti-inflammatory agent. Previous reports are in agreement with our data 
and concluded that ketamine, through glutamate activation inhibiting histamine release 
through mGlu2/3 receptors and immunomodulatory abilities, could result in the decrease 
of stimulated histamine. Most interestingly, the overall effect is on serotonin, in a manner 




In this report we investigated the effect of acute ketamine administration on 
histamine and serotonin in vivo. In the posterior hypothalamus, we found that ketamine 
caused a rapid and sustained decrease in histamine amplitude and lessened histamine’s 
inhibition of serotonin 100 min following administration. Additionally, we confirmed the 
increase in ambient serotonin by showing ketamine increased basal hippocampal serotonin 
in a similar fashion to the SSRI escitalopram, despite its completely different mode of 
action. The therapeutic effects of rapid acting antidepressants like ketamine are still being 
uncovered. Our data provide new insights into the effects of rapid acting antidepressants 






 The relationship of chemicals in the brain is delicate and dynamic. Histamine and 
serotonin are two important bioamines that regulate many different processes within the 
brain and body. Their actions and modulation are still being studied to fully understand the 
impact histamine and serotonin have on brain disorders. However, analyzing the 
underlying neurochemical changes of these two molecules has been challenging due to the 
lack of robust analytical tools. This work continued previous Hashemi lab investigations 
to uncover the intricate relationship histamine and serotonin have in the brain. 
 In this dissertation, I first reviewed the currently available tools for neurochemical 
analysis and their respective advantages and drawbacks in Chapter 2. I then used FSCV to 
investigate how CNS histamine responded to pharmacological challenge in male and 
female mice in Chapter 3. I found that the histamine system is highly conserved between 
male and female mice, owing to the brain’s homeostatic regulation. However, I determined 
that female mice appear to have a higher level of immune regulation mediated by H3 
receptors. Next, I used a genetically modified mouse model to investigate the transport 
mechanisms of histamine clearance in the brain and rule out SERT’s contribution to 
histamine uptake in Chapter 4. With a better understanding of the male and female and 
transport systems, I applied histamine FSCV to a model of chronic stress and chronic 
inflammation (chronic mild stress behavioral paradigm) in Chapter 5. I showed that brain 
histamine is elevated in this model of chronic stress/inflammation which is important in 
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the context of histamine’s ability to inhibit serotonin release through H3 receptors. Finally, 
I studied the effects of the newly approved antidepressant, ketamine in Chapter 6. 
Ketamine’s antidepressant effects are rapid, relatively short lived requiring repeated 
injections, and broadly not well understood. Unlike common antidepressants that target 
traditional monoamines, ketamine targets the glutamatergic system and is thought to 
modulate monoamines through glutamate and GABA. Knowing how histamine is changed 
during depression and inflammation, and that in addition to its antidepressant effects, 
ketamine has been shown to be anti-inflammatory, understanding how ketamine affected 
histaminergic transmission provided novel information on its neurochemical mechanism. 
 This dissertation pushed our understanding of the co-modulation of histamine and 
serotonin and how these two neurotransmitters respond to pharmaceutical targeting. Future 
studies will have to further investigate the ability of female mice to regulate histamine 
levels in the brain and the influence of cycling hormones on that regulation. Studies using 
post-menopausal mice, ovariectomized mice, or mice given estrogen blocking compounds 
should yield a clearer understanding of female H3 receptor control.  
 I applied histamine FSCV to a model of behaviorally induced chronic stress. In the 
future, we plan to expand the application of histamine FSCV to other models of chronic 
inflammation, neuroinflammation, and neurodegeneration. One such model is the 
chemically induced Parkinson’s disease model MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) mouse. Additionally, due to the increased prevalence and risk posed 
by environmental toxins in today’s world, we are in a unique position to study how 




 Chapter 3 investigated a substantial amount of pharmacology of the histamine 
system. We plan to collaborate with mathematicians to create a mathematical model 
representing the physiological function of a histamine synapse. The model will encompass 
both male and female aspects as well as the modulation of histamine and serotonin to create 
a more complete picture than two separate systems. Ultimately, the product would be 
applied to data obtained from neurodegenerative or inflammation animal models to 
highlight key criteria (eg. release, reuptake, vesicular packaging) causing deficits. 
 Overall, this dissertation showcased the power of simultaneous, real-time 
neurochemical measurements via FSCV. The continued advancement of our understanding 
of the intricate relationships neurotransmitter systems have with one another will aid in the 
development of novel strategies and therapies to manage the enormous burden psychiatric 
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SUPPLEMENTAL FIGURES FOR CHAPTER 3 
 
Figure B1: Representative images for estrous cycle determination. (A) 




Figure B2: Electrode placement in the posterior hypothalamus. Layered 
brain slices and brain atlas images show the placement of CFM in 





SUPPLEMENTAL MATERIAL FOR CHAPTER 5 
 
Figure C1 CMS-treated mice have larger 
stimulated histamine area under the curve. Violin 
plot comparing the area under the curve of 
stimulated histamine between non-stress control 
mice and CMS-treated mice. (AUC control: 14.51 
± 2.35 µM•s; CMS: 25.50 ± 2.80 µM•s; Wilcoxon 
rank-sum test, p=0.02) 
